US20220402967A1 - Sterol derivatives and preparation method and uses thereof - Google Patents
Sterol derivatives and preparation method and uses thereof Download PDFInfo
- Publication number
- US20220402967A1 US20220402967A1 US17/820,553 US202217820553A US2022402967A1 US 20220402967 A1 US20220402967 A1 US 20220402967A1 US 202217820553 A US202217820553 A US 202217820553A US 2022402967 A1 US2022402967 A1 US 2022402967A1
- Authority
- US
- United States
- Prior art keywords
- compound
- formula
- present
- extract
- monascus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 229930182558 Sterol Natural products 0.000 title abstract description 5
- 150000003432 sterols Chemical class 0.000 title abstract description 5
- 235000003702 sterols Nutrition 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 99
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 109
- 239000000284 extract Substances 0.000 claims description 68
- 235000007164 Oryza sativa Nutrition 0.000 claims description 41
- 235000009566 rice Nutrition 0.000 claims description 39
- 239000008802 xuezhikang Substances 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 17
- 241000209094 Oryza Species 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 42
- 239000003814 drug Substances 0.000 abstract description 36
- 239000004367 Lipase Substances 0.000 abstract description 28
- 102000004882 Lipase Human genes 0.000 abstract description 28
- 108090001060 Lipase Proteins 0.000 abstract description 28
- 235000019421 lipase Nutrition 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract description 17
- 210000004881 tumor cell Anatomy 0.000 abstract description 16
- 150000002148 esters Chemical class 0.000 abstract description 15
- 150000003839 salts Chemical class 0.000 abstract description 15
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract description 13
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 67
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 47
- 230000000694 effects Effects 0.000 description 44
- 238000011282 treatment Methods 0.000 description 44
- 238000010828 elution Methods 0.000 description 42
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 38
- 239000003208 petroleum Substances 0.000 description 38
- 240000007594 Oryza sativa Species 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- 208000008589 Obesity Diseases 0.000 description 32
- 235000020824 obesity Nutrition 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 26
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 25
- 229940040461 lipase Drugs 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 238000011321 prophylaxis Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000002137 ultrasound extraction Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 125000004430 oxygen atom Chemical group O* 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 229940126062 Compound A Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 8
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000000459 effect on growth Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000002751 lymph Anatomy 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- -1 polyoxyethylene Polymers 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical group CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 8
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 7
- 230000005526 G1 to G0 transition Effects 0.000 description 7
- 239000005642 Oleic acid Substances 0.000 description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000000431 effect on proliferation Effects 0.000 description 5
- 239000002532 enzyme inhibitor Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 4
- LBWTUPWVHQTYRC-UHFFFAOYSA-N CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)C Chemical compound CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)C LBWTUPWVHQTYRC-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 0 [1*]C1CCC2(C)C(=CC=C3C2CCC2(C)C3CC3OC(C([3*])C(C)C([4*])(C)C)C([2*])(C)C32)C1 Chemical compound [1*]C1CCC2(C)C(=CC=C3C2CCC2(C)C3CC3OC(C([3*])C(C)C([4*])(C)C)C([2*])(C)C32)C1 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 229960004844 lovastatin Drugs 0.000 description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- BISLTBNBBNNYFZ-UHFFFAOYSA-N CC(C(O)C(O)C(C)(O)C1C(O)CC2C3=CC=C4CC(O)CCC4(C)C3CCC21C)C(C)(C)O.CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)O Chemical compound CC(C(O)C(O)C(C)(O)C1C(O)CC2C3=CC=C4CC(O)CCC4(C)C3CCC21C)C(C)(C)O.CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)O BISLTBNBBNNYFZ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 235000007189 Oryza longistaminata Nutrition 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 229910001431 copper ion Inorganic materials 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- MKDKGLNKTMDNHY-WXUKJITCSA-N (e)-n,5-dihydroxy-n-[3-[5-[3-[hydroxy-[(e)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide Chemical compound OCCC(/C)=C/C(=O)N(O)CCCC1NC(=O)C(CCCN(O)C(=O)\C=C(/C)CCO)NC1=O MKDKGLNKTMDNHY-WXUKJITCSA-N 0.000 description 1
- XOVDDIXMUCMHEJ-KVVVOXFISA-N (z)-octadec-9-enoic acid;toluene Chemical class CC1=CC=CC=C1.CCCCCCCC\C=C/CCCCCCCC(O)=O XOVDDIXMUCMHEJ-KVVVOXFISA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZSZIFDCXKQQDEY-UWODLYMDSA-N 2-[(E,2S,5R)-5-[(3S,9S,10R,13R,14R,17R)-3-hydroxy-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]hex-3-en-2-yl]propane-1,1,1,3,3,3-hexol Chemical compound OC(C([C@H](/C=C/[C@H]([C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C)C)C(O)(O)O)(O)O ZSZIFDCXKQQDEY-UWODLYMDSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- JQFKZDIJUGJASJ-UHFFFAOYSA-N C.C.CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)C.CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)O Chemical compound C.C.CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)C.CC(C(O)C1OC2CC3C4=CC=C5CC(O)CCC5(C)C4CCC3(C)C2C1(C)O)C(C)(C)O JQFKZDIJUGJASJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001134456 Homo sapiens Pancreatic triacylglycerol lipase Proteins 0.000 description 1
- 206010020564 Hyperadrenocorticism Diseases 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241001113787 Strychnos Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- SVOAENZIOKPANY-CVBJKYQLSA-L copper;(z)-octadec-9-enoate Chemical compound [Cu+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O SVOAENZIOKPANY-CVBJKYQLSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 102000046759 human PNLIP Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002365 multiple layer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000011514 vinification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof.
- Monascus -fermented rice is a purple red rice koji prepared by using rice as raw material via fermentation with Monascus.
- Monascus -fermented rice is also called Danqu ( ) in ancient China, which is obtained via fermentation in which koji or mold culture with Monascus as main component is cultured on cooked rice; it is red color, and thus is also called as red koji, red rice, or red wine dreg; and it is also called Fujian koji, Fujian rice, etc., because it is primarily produced in Fujian.
- Monascus -fermented rice is a traditional Chinese medicine as both food and drug. It had been widely used for food coloring, wine-making, fermentation, Chinese medicine as early as in ancient times.
- ⁇ Principle of Correct Diet> has the recordation that Monascus -fermented rice is of “sweet taste and neutral nature and smooth in taste, non-toxic” and “invigorating spleen, supplementing Qi, warming spleen and stomach”;
- ⁇ Compendium of Materia Medica> has the recordation of “sweet, warm, non-toxic”, “capable of treating dysmenorrheal, extravasated blood after delivery, by grinding with rice wine and then drinking”;
- ⁇ Addendum for Amplification on Materia Medica> has recordation of “activating blood, helping digestion, invigorating spleen and warming stomach, capable of treating red and white vaginal discharge and diarrhea, as well as traumatic injury”.
- Monascus -fermented rice functions of Monascus -fermented rice such as hypolipemic, lowering blood pressure, hyperglycemic, anti-obesity, anticancer, prophylaxis and treatment of senile dementia and osteoporosis are continuously revealed, which add more connotations to traditional Monascus -fermented rice.
- Xuezhikang capsules are an efficient, safe and modern Chinese medicine for lipid regulation which is prepared by Monascus fermentation and developed by Beijing Peking University WBL Biotechnology Co., Ltd. It is useful in treatment of indications such as cardiovascular and cerebrovascular diseases caused by hyperlipemia and atherosclerosis. Its action mechanism is of inhibiting endogenous cholesterol synthesis, reducing serum total cholesterol (TC), blood triglyceride (TG), low density lipoprotein (LDL) and elevating high density lipoprotein (HDL) level via inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA).
- Xuezhikang capsules are of an alcohol extract of Monascus -fermented rice, which are rich in a series of natural statins.
- Xuezhikang capsules further contain pigment, isoflavone, sterol, 20 kinds of amino acids, unsaturated fatty acids, and many trace elements.
- isoflavone sterol
- 20 kinds of amino acids unsaturated fatty acids
- trace elements many trace elements.
- Xuezhikang may further comprise some unknown anticancer ingredients. Thus, it is also in need to find novel anticancer compounds.
- Obesity is a universal internal secretion metabolic disease, and intends to be wide-spread worldwide. It not only affects posture and activity, but also is closely associated with hyperlipemia, atherosclerosis, coronary heart disease, diabetes and so on. The occurrence of obesity relates to many factors, such as genetic factors, environmental factors, dietary habits, among which high fat diet is an important factor of obesity. In recent years, drug therapy is an effective means for treatment of obesity, which its therapeutic goal is usually achieved by reducing fat absorption. Lipases of pancreas and stomach are necessary for digestion and absorption of fats in intestinal tract.
- lipase inhibitors can effectively inhibit decomposition and catalysis effects of lipases on fats in intestinal tract, so as to achieve the goal of reduction of fat absorption, control and treatment of obesity (CHEN Jin, etc., Advances in studying drug therapy of obesity, Chinese Archives of Traditional Chinese Medicine, 2007, 25(5):947-948; WU Jing, etc., Advances in drug therapy of obesity, Medical Recapitulate, 2006, 12(11):693-693).
- sibutramin weight-reducing aid acting on central nervous
- orlistat lipase inhibitor in gastrointestinal tract
- sibutramin has side-effects mainly including thirst, astriction, dizziness and insomnia
- orlistat has adverse reactions mainly including gastrointestinal symptoms, such as diarrhea, bellyache, oily flecks, flatulence, etc., and their long-term effects should be further evaluated.
- the inventors of the present invention obtain a new sterol derivative, and the inventors surprisingly find the compound of the present invention can effectively inhibit HMG-CoA reductase, and thus is a potential drug for reduction or regulation of blood-fat or prophylaxis and/or treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic.
- the inventors further surprisingly find that: 1) the compound of the present invention can effectively inhibit proliferation of cancer cells (tumor cells), and is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of cancers; 2) the compound of the present invention can effectively inhibit activity of lipase, and thus is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
- cancer cells tumor cells
- lipase a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
- One aspect of the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof,
- R 1 is selected from the group consisting of —OH, ⁇ O (carbonyl), H, and C 1 -C 3 alkyl;
- R 2 is selected from the group consisting of —OH, H, and C 1 -C 3 alkyl
- R 3 is selected from the group consisting of —OH, ⁇ O, H, and C 1 -C 3 alkyl;
- R 4 is selected from the group consisting of —OH, H, and C 1 -C 3 alkyl
- R 1 , R 2 , R 3 , and R 4 are —OH.
- sites for forming the ester or ether are none, one, two, three or four of R 1 , R 2 , R 3 , and R 4 .
- R 1 is —OH or ⁇ O (carbonyl)
- R 2 , R 3 and R 4 are all H.
- the compound or pharmaceutically acceptable salt, ester or ether of any one of items of the present invention is a compound of Formula II as follows, or a pharmaceutically acceptable salt, ester or ether thereof,
- the compound of Formula II has chemical name of: 16,22-epoxy-ergosta-5,7-dien-3,20,23,25-tetraol.
- ester or ether of any one of items of the present invention said ester is selected from the group consisting of formate, acetate, propionate and sulfonate; said ether is tert-butyl-dimethyl silyl ether; specifically, said sulfonate group is p-tolylsulfonate or trifluoromethylsulfonate.
- the present invention further relates to a hydrate or solvate of the compound of Formula I or the compound of Formula II.
- Another aspect of the present invention relates to a method for preparing the compound of Formula I or the compound of Formula II, comprising the following steps:
- Monascus -fermented rice and/or alcohol extract of Monascus -fermented rice e.g., content of Xuezhikang capsules, which is a dry powder
- the alcohol extract can be obtained by the following method: using 50%-100% ethanol or 50%-100% methanol in 2-6 times by volume as solvent to perform ultrasonic extraction once or more times, 20-40 minutes each time, combining extracted solutions, removing solvent to obtain the alcohol extract.
- Monascus -fermented rice can be directly used as raw material, and extracting steps are substantively the same for obtain the content of Xuezhikang, but Monascus -fermented rice has a relatively lower content of the compound.
- the specific strains of Monascus -fermented rice are not specifically limited, but include any strains of Monascus.
- Xuezhikang capsules e.g., those manufactured by Beijing Peking University WBL Biotechnology Co., Ltd. are commercially available in hospitals or pharmacies.
- step 2) loading the refined extract obtained in step 1) on a silica gel column for separation, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- step 3 taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to C18 reversed phase chromatography, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence;
- step 3 taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting the fractions of chromatographic peak at 9.2 minute; and
- step 5) freeze-drying the product of step 4) to obtain a compound of Formula I or Formula II.
- the preparation method according to any one items of the present invention meets any one or more of following items (1) to (9):
- said organic solvent is preferably dichloromethane
- step 1) said ultrasonic extraction is performed for 3 times;
- step 1) the solvent is removed by concentration under reduced pressure
- step 2) the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- step 3 the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- step 3 the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- step 4 the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- step 4 the fractions of collected chromatographic peak at 9.2 minute are combined;
- the conditions for freeze-drying are: cold trap temperature is ⁇ 40° C. to ⁇ 85° C., vacuum degree is 0-100 Pa; preferably, cold trap temperature is ⁇ 50° C. to ⁇ 82.7° C., vacuum degree is 2-13 Pa; more preferably, cold trap temperature is ⁇ 82.7° C., vacuum degree is 2 Pa, or cold trap temperature is ⁇ 50° C., vacuum degree is 8.5 Pa.
- hexahydroxyergosterol e.g., 3,16,20,22,23,25-hexahydroxy-ergosterol, briefly called as Compound A
- the Compound A can be prepared by referring to the preparation method of Chinese Patent Publication CN101469014A (application number is 200710304346.0).
- the molar ratio of Compound A to p-toluenesulfonic acid monohydrate is 5:1-2:1; specifically, Compound A and p-toluenesulfonic acid monohydrate in toluene solution react under refluxing for 5-10 hours to obtain the compound of Formula II.
- the molar ratio of Compound A to 2,4,6-triisopropylsulfonyl chloride is 5:1 to 2:1; specifically, Compound A and 2,4,6-triisopropylsulfonyl chloride in pyridine solution react at a temperature of 30° C. to 70° C. for 10 to 30 hours to obtain the compound of Formula II.
- the compound of Formula II under certain conditions can generate different derivatives, such as ester derivatives, including but not being limited to acetate, sulfonate.
- the ester derivatives can be prepared by reacting a compound of Formula II with a common anhydride, acyl chloride, sulfonyl chloride, sulfonic acid.
- a catalyst useful in reaction with anhydride can be selected from pyridine, concentrated sulfuric acid, NaHCO 3 , etc. For examples:
- Tetraacetate of compound of Formula II (corresponding to a compound of Formula I, in which R 1 ⁇ R 2 ⁇ R 3 ⁇ R 4 ⁇ —OC( ⁇ O)—CH 3 ) is prepared by: reacting a compound of Formula II with acetic anhydride as reaction agent and solvent in the presence of a catalytic amount of concentrated sulfonic acid at 40-80° C. for 1-3 hours.
- Tetra-p-tolylsulfonate of compound of Formula II (corresponding to a compound of Formula I, in which R 1 ⁇ R 2 ⁇ R 3 ⁇ R 4 ⁇ —OTs) is prepared by: reacting a compound of Formula II with p-toluenesulfonyl chloride in molar ratio of 1:4 to 1:8 in dichloromethane at 20-40° C. in the presence of triethylamine as acid scavenging agent.
- Tetra(trifluoromethylsulfonate) of compound of Formula II (corresponding to a compound of Formula I, in which R 1 ⁇ R 2 ⁇ R 3 ⁇ R 4 ⁇ CF 3 SO 3 —) is prepared by: reacting a compound of Formula II with trifluoromethanesulfonic anhydride in molar ratio of 1:4 to 1:6 in dichloromethane at 20-30° C. in the presence of pyridine for 1-5 hours.
- a compound of Formula II under certain conditions can also form silyl ether derivative, such as tert-butyl-dimethyl silyl ether of compound of Formula II.
- silyl ether derivative such as tert-butyl-dimethyl silyl ether of compound of Formula II.
- Tetra(tert-butyl-dimethyl silyl ether) of compound of Formula II (corresponding to a compound of Formula I, in which R 1 ⁇ R 2 ⁇ R 3 ⁇ R 4 ⁇ TBDMSO—) is prepared by: reacting a compound of Formula II with sodium hydride in molar ratio of 1:4 in tetrahydrofuran, then reacting with tert-butyl-dimethylchlorosilane at 20-40° C. for 1-3 hours.
- the extract according to any one of items of the present invention is an extract of dry powder of content of Xuezhikang capsules or an extract of Monascus -fermented rice.
- the compound of Formula II has a content of 0.0001-5% (w/w), 0.001-2% (w/w) or 0.001-1% (w/w).
- the content of compound of Formula II can be regulated by appropriate concentration of the extract of the present invention.
- the concentration can be performed by a common method known by those skilled in the art.
- the extract according to any one of items of the present invention is any one of following (1) to (3):
- compositions which comprises a compound of Formula I or Formula II, and/or the extract of any one of items of the present invention; optionally, further comprises a pharmaceutically acceptable carrier or excipient.
- the composition is a pharmaceutical composition.
- the pharmaceutical composition of the present invention comprises 0.1-90 wt % of a compound of Formula I or Formula II and/or pharmaceutically acceptable salt thereof.
- the pharmaceutical composition can be prepared according to a known method in the art. If necessary, the compound of Formula I or Formula II and/or pharmaceutically acceptable salt thereof can be combined with one or more solid or liquid pharmaceutically acceptable excipients and/or adjuvants to obtain a suitable administration form or dosage form.
- the compound of Formula I or Formula II or pharmaceutically acceptable salt thereof or pharmaceutical composition comprising it of the present invention can be administrated in unit dosage form, and administration route can be intestinal administration or parenteral administration, such as oral, muscle, subcutaneous, nasal, mouth mucosa, skin, peritoneum, or rectum administration.
- Administration dosage form can be, for example, tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, and lyophilized powder injections. They can be normal preparations, sustained-release preparations, controlled-release preparations and various particulate delivery systems.
- carrier examples include starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binding agents, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia mucilage, gelatin mucilage, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone; disintegrants, such as dry starch, alginates, agar powders, laminarin, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid esters, sodium dodecyl
- disintegrants such as dry starch, alginates, agar powders, laminarin, sodium bicarbonate and citric acid, calcium carbonate, poly
- carriers can also be further processed to form coated tablets, such as sugar coated tablets, thin membrane coated tablets, enteric-coated tablets, or double-layer tablets or multiple-layer tablets.
- various carriers known in the art can be widely used.
- the example of carriers are, for example, diluents or absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc powder, etc.; binding agents, such as acacia gum, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrating agents, such as agar powder, dry starch, alginates, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc.
- suppositories as administration unit, various carriers known in the art can be widely used.
- the examples of carriers are, for example, polyethylene glycol, lecithin, cocoa butter, fatty alcohols, esters of fatty alcohols, gelatin, semi-synthesized glycerides, etc.
- the compound of Formula I or Formula II or pharmaceutically acceptable salt thereof as effective ingredient is mixed with the above various carriers, and the obtained mixture is filled in hard gelatin capsules or soft capsules.
- the compound of Formula I or Formula II or pharmaceutically acceptable salt thereof as effective ingredient can also be processed to form microcapsules, then suspended in aqueous medium to form a suspension, or filled in hard capsules or processed to form an injection.
- injectable preparations for example, solutions, emulsions, lyophilized powder injections and suspensions
- all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, propane-1,3-diol, ethoxylated isostearyl alcohol, multiple-oxidized isostearyl alcohol, polyoxyethylene sorbitol fatty acid ester, etc.
- a suitable amount of sodium chloride, glucose or glycerol can be added to injection preparations, and conventional auxiliary solvents, buffers, pH regulators and so on can also be added.
- coloring agents if necessary, coloring agents, preservatives, perfumes, correctants, sweetening agents or other materials can also be added to the pharmaceutical preparations.
- the dose of the compound of Formula I or Formula II or pharmaceutically acceptable salt thereof of the present invention depends on many factors, such as property and severity of the disease to be prevented or treated, patient's or animal's gender, age, bodyweight and individual reaction, the specific compound to be used, administration route, and administration frequency.
- the dose can be administered in single dose form or in several batches, such as 2-, 3- or 3-batches.
- composition in the text refers to a product comprising various components in designated amounts, and any product directly or indirectly derived from various components in designated amounts in combination.
- the actual dose levels of various active components in the pharmaceutical composition of the present invention can be changed so that the expected therapeutic effects can be achieved via the resultant amount relative to specific patient, composition and administration manner.
- the dose level must be selected according to the activity of the specific compound, administration route, severity of disease to be treated, patient's condition and medical history.
- the practice in the art is that the dose of compound gradually increases from a level lower than that for achieving the desired therapeutical effects to a dose capable of achieving the desired therapeutical effects.
- Another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament for reduction or regulation of blood-fat or prophylaxis and/or treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic.
- Another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a HMG-CoA reductase inhibitor.
- Another aspect of the present invention relates to a method for inhibiting HMG-CoA reductase in vivo or in vitro, comprising the step of using an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention.
- Example 1 confirm that the compound of the present invention has activity of inhibiting HMG-CoA reductase, and the activity is dose dependent.
- Another aspect of the present invention relates to a method for reduction or regulation of blood-fat or prophylaxis and/or treatment and/or adjunctive treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic, comprising the step of administering an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention.
- Another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament for prophylaxis and/or treatment and/or adjunctive treatment of a cancer; specifically, said cancer is colon cancer, liver cancer, lymph cancer, or melanoma.
- the method for inhibiting tumor cells is a method for inhibiting tumor cells in vitro or in vivo.
- Example 2 confirm the compound of the present invention can effectively inhibit tumor cells.
- Another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament or for prophylaxis and/or treatment and/or adjunctive treatment of obesity or a disease associated with obesity anti-obesity agent; specifically, said disease associated with obesity is hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- Another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament or an agent for inhibiting lipase.
- Another aspect of the present invention relates to a method for inhibiting lipase, comprising the step of using an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention.
- said method for inhibiting lipase is a method for inhibiting lipase in vivo or in vitro.
- Example 3 confirm the compound of the present invention can effectively inhibit lipase.
- Another aspect of the present invention relates to a method for prophylaxis and/or treatment and/or adjunctive treatment of obesity or a disease associated with obesity or a method for losing weight; specifically, said disease associated with obesity is hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- a compound of the present invention in a therapeutically and/or prophylactically and/or adjunctively therapeutically effective amount can be used in form of pure compound, or in form of pharmaceutically acceptable esters or predrugs thereof (if they exist).
- the compound can be administered via a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients. It should be understood that the total amount per day of the compound or composition of the present invention must be determined by a physician within the range of reliable medical decisions.
- the specific therapeutically amount must be determined based on various factors, including the diseases to be treated and severity thereof, the activity of the used specific compound, the used specific composition, the age, body weight, general health status, gender and food of patient, the administration time and route and excretory rate of the used specific compound, the drug(s) administered in combination or simultaneously with the specific compound, and similar factors well known in the art of medicine.
- the dose of a compound of Formula I for mammals especially human can be 0.001-1000 mg/kg body weight per day, such as 0.01-100 mg/kg body weight per day, 0.01-10 mg/kg body weight per day.
- the compound according to the present invention can effectively prevent and/or treat the various diseases and disorders as mentioned in the present invention.
- C 1 -C 3 alkyl comprises methyl, ethyl, propyl and isopropyl.
- the term “obesity” includes but is not limited to simple obesity (without a significant cause in internal secretion and metabolism, relating to heredity and feeding habits), secondary obesity (usually associating to some diseases such as hyperadrenocorticism, which could be eliminated when the diseases are cured).
- the obesity can be obesity in a mammal, and the mammal comprises human and pig.
- diabetes includes but is not limited to hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- lipase (enzyme classification number: EC3.1.1.3) includes but is not limited to a lipase of mammal, such as a lipase of human or a lipase of pig, the lipase of human can be human pancreatic lipase, and the lipase of pig can be porcine pancreatic lipase.
- the term “effective amount” refers to a dose that can fulfill treatment, prophylaxis and or remission of the diseases or disorders of the present invention in a subject.
- a percentage content of an ingredient refers to a weight percentage (w/w).
- the present invention further relates to the following aspects 1 to 22:
- any one of items (1) to (4) in the manufacture of a medicament for prophylaxis and/or treatment and/or adjunctive treatment of a cancer specifically, said cancer is colon cancer, liver cancer, lymph cancer, or melanoma,
- R 1 is selected from the group consisting of —OH, ⁇ O, H, and C 1 -C 3 alkyl;
- R 2 is selected from the group consisting of —OH, H, and C 1 -C 3 alkyl
- R 3 is selected from the group consisting of —OH, ⁇ O, H, and C 1 -C 3 alkyl;
- R 4 is selected from the group consisting of —OH, H, and C 1 -C 3 alkyl
- R 1 , R 2 , R 3 , and R 4 are simultaneously —OH;
- composition which comprises any one of the above items (1)-(3).
- any one of items (1) to (4) of Aspect 1 in the manufacture of a medicament or an agent for inhibiting tumor cells in vivo or in vitro; specifically, said tumor cells are colon cancer cells, liver cancer cells, lymph cancer cells, or melanoma cells.
- Monascus -fermented rice and/or alcohol extract of Monascus -fermented rice e.g., content of Xuezhikang capsules, which is a dry powder
- step 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- step 3 taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- step 3 taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- step 1) said organic solvent is dichloromethane
- step 1) said ultrasonic extraction is performed for 3 times;
- step 1) the solvent is removed by concentration under reduced pressure
- step 2) the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- step 3 the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- step 3 the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- step 4 the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- step 4 the fractions of collected chromatographic peak at 9.2 minute are combined.
- composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- a method for inhibiting tumor cells in vivo or in vitro comprising the step of using an effective amount of any one of the items (1) to (4) of Aspect 1; specifically, said tumor cells are colon cancer cells, liver cancer cells, lymph cancer cells, or melanoma cells.
- the extract of item (3) is an extract of Monascus -fermented rice and/or an extract of an alcohol extract of Monascus -fermented rice (e.g., content of Xuezhikang capsules).
- extract of item (3) is the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the following steps 1) to 2); or the elution fraction of methanol-water (50:50-75:25) as prepared in the following steps 1) to 3); or fractions of chromatographic peak at 9.2 minute as prepared in the following steps 1) to 4):
- Monascus -fermented rice and/or alcohol extract of Monascus -fermented rice e.g., content of Xuezhikang capsules, which is a dry powder
- step 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- step 3 taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- step 3 taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- step 1) said organic solvent is dichloromethane
- step 1) said ultrasonic extraction is performed for 3 times;
- step 1) the solvent is removed by concentration under reduced pressure
- step 2) the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- step 3 the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- step 3 the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- step 4 the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- step 4 the fractions of collected chromatographic peak at 9.2 minute are combined.
- composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- R 1 is selected from the group consisting of —OH, ⁇ O, H, and C 1 -C 3 alkyl;
- R 2 is selected from the group consisting of —OH, H, and C 1 -C 3 alkyl
- R 3 is selected from the group consisting of —OH, ⁇ O, H, and C 1 -C 3 alkyl;
- R 4 is selected from the group consisting of —OH, H, and C 1 -C 3 alkyl
- R 1 , R 2 , R 3 , and R 4 are simultaneously —OH;
- composition which comprises any one of the above items (1)-(3).
- Monascus -fermented rice and/or alcohol extract of Monascus -fermented rice e.g., content of Xuezhikang capsules, which is a dry powder
- step 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- step 3 taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- step 3 taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- step 1) said organic solvent is dichloromethane
- step 1) said ultrasonic extraction is performed for 3 times;
- step 1) the solvent is removed by concentration under reduced pressure
- step 2) the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- step 3 the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- step 3 the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- step 4 the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- step 4 the fractions of collected chromatographic peak at 9.2 minute are combined.
- composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- a method for inhibiting lipase in vivo or in vitro comprising a step of using an effective amount of any one of the items (1) to (4) of Aspect 12.
- the extract of item (3) is an extract of Monascus -fermented rice and/or an extract of an alcohol extract of Monascus -fermented rice (e.g., content of Xuezhikang capsules).
- the extract of item (3) is the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the following steps 1) to 2); or the elution fraction of methanol-water (50:50-75:25) as prepared in the following steps 1) to 3); or fractions of chromatographic peak at 9.2 minute as prepared in the following steps 1) to 4):
- Monascus -fermented rice and/or alcohol extract of Monascus -fermented rice e.g., content of Xuezhikang capsules, which is a dry powder
- step 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- step 3 taking then elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- step 3 taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- step 1) said organic solvent is dichloromethane
- step 1) said ultrasonic extraction is performed for 3 times;
- step 1) the solvent is removed by concentration under reduced pressure
- step 2) the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- step 3 the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- step 3 the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- step 4 the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- step 4 the fractions of collected chromatographic peak at 9.2 minute are combined.
- composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- the compound of the present invention can effectively inhibit HMG-CoA reductase, and has dose-dependent activity for inhibiting HMG-CoA reductase; so that it is a potential drug for reduction or regulation of blood-fat or for prophylaxis and/or treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic.
- the compound of the present invention can effectively inhibit the proliferation of cancer cells (tumor cells), and has inhibition activity in concentration-effect relation; so that it is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of cancers.
- the compound of the present invention can effectively inhibit the activity of lipase, and has inhibition activity in concentration-effect relation; so that it is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
- FIG. 1 inhibition curve of a compound of Formula II on growth of HCT116 cells.
- FIG. 2 inhibition curve of a compound of Formula II on growth of H22 cells.
- FIG. 3 inhibition curve of a compound of Formula II on growth of HepG2 cells.
- FIG. 4 inhibition curve of a compound of Formula II on growth of S180 cells.
- FIG. 5 inhibition curve of a compound of Formula II on growth of YAC-1 cells.
- FIG. 6 inhibition curve of a compound of Formula II on growth of THP1 cells.
- FIG. 7 inhibition curve of a compound of Formula II on growth of U937 cells.
- FIG. 8 inhibition curve of a compound of Formula II on growth of B16-F10 cells.
- FIG. 9 absorbance working curve of oleic acid.
- HSQC and HMBC spectra were analyzed in combination and showed that the 6 carbon atoms linked to oxygen atoms were separately assigned to 4 carbon atoms linked to 4 hydroxyls (70.5, 72.4, 74.5, 80.4 ppm) and 2 carbon atoms linked to the residual one oxygen atom (83.8, 84.4 ppm).
- Deep analysis of HMBC spectra showed that the 5 th ring system was a 5-membered ring consisting of C-16 (83.8 ppm), C-17 (66.9 ppm), C-20 (80.4 ppm), C-22 (84.4 ppm) and oxygen atom. This satisfied degree of unsaturation and number of carbon atoms linked to oxygen atoms.
- TBDMS-C1 (tert-butyldimethylchlorosilane) (5.53 g, 36.8 mmol) was dissolved in 10 mL THF, added dropwise to the above reaction solution under stirring, the speed of dropwise adding was controlled so that the reaction temperature was not extremely high, after end of dropwise adding, the reaction was continued at room temperature under stirring for 1.5 hours.
- the reaction solution was poured in water, extracted with dichloromethane; the organic phase was washed with water to neutrality, washed with saturated brine, dried with anhydrous sodium sulfate.
- the filtrate was concentrated, separated with column chromatography, to obtain tetra (tert-butyl-dimethyl-silyl ether) of compound of Formula II.
- Rat liver microsomes (HMG-CoA reductase)—, could be commercially available or prepared by the following preparation method: taking out liver of male rat, washing with KESD buffer solution, centrifuging under 1200 g for 15 minutes, collecting supernatant, then centrifuging under 105,000 g twice, 90 minutes for each time, and collecting centrifugation deposit. The centrifugation deposit was added with 8.3% of glycerol, heated with 37° C. bath for 1 hour. The crude product of rat liver microsomes was purified with saturated ammonium sulfate, and 35-50% of purified fraction was collected. The purified fraction obtained could be stored in ⁇ 80° C. refrigerator.
- Potassium chloride potassium dihydrogen phosphate, ethylenediamine tetraacetic acid, dithiothreitol—purchased from Beijing Chemical Reagents Co., Ltd.;
- HMG-CoA 3-hydroxy-3-methylglutary coenzyme A
- Compound of Formula II was dissolved in 75% ethanol solution, with initial concentration of 8.0 mg/mL, and diluted in gradient manner, to reach 4.0 mg/mL, 2.0 mg/mL, 1.0 mg/mL; lovastatin was used as positive control, dissolved with 75% ethanol solution to reach concentration of 2.0 mg/mL; in the test system, total volume was 250 ⁇ L, concentrations of ingredients were separately: potassium chloride 200 mM, potassium dihydrogen phosphate 160 mM, ethylenediamine tetraacetic acid 4 mM, dithiothreitol 10 mM, nicotinamide adenine dinucleotide and 3-hydroxy-3-methylglutary coenzyme A as two substrates separately had concentrations of: 200 ⁇ M and 50 ⁇ M, pH6.8, 30 ⁇ L of enzyme was added, 4 test groups were separately added with 10 ⁇ L of new compound solutions with different concentrations, the positive control group was added with 10 ⁇ L of lovastatin
- test results showed that the compound of the present invention, especially, the compound of Formula II, had inhibition effect on activity of HMG-CoA reductase, and presented concentration-effect relationship. Its IC 50 value was about 250 ⁇ g/mL, which indicated that the compound has good inhibition effects on activity of HMG-CoA reductase.
- ester derivatives or ether derivatives of compound of Formula II for example, “tetraacetate of compound of Formula II”, “tetra-p-tolylsulfonate of compound of Formula II”, “tetra(trifluoromethylsulfonate) of compound of Formula II” and “tetra(tert-butyl-dimethyl-silyl ether) of compound of Formula II” as prepared in Examples 6-9 also had similar activity of inhibiting HMG-CoA reductase.
- HCT116 and H22 purchased from Korean cell line bank, Seoul, Korea;
- MTT was purchased from Amresco; RPMI1640 and double antibody were purchased from Sigma; fetal bovine serum (FBS) was purchased from Gibco in USA; all other reagents were of analytical purity and made in China.
- FBS fetal bovine serum
- Cancer cells of exponential growth phase were inoculated on 96-well plate, 2 ⁇ 10 4 cells/well, added with drug until final drug concentrations were: 500, 250, 125, 62.5, 31.25, 15.625 and 7.8125 ⁇ g/mL, cultured at 37° C. in 5% CO 2 cell culture incubator for 72 hours, then added with MTT, 10 ⁇ L/well, incubated in dark at 37° C. for 4 hours, culture medium was removed, 150 ⁇ L of DMSO or acidified isopropanol was added, vibrated for 5 minutes, and then OD values were measured under wavelength of 570 nm. This was repeated for 3 times, and a blank control was set.
- These cell strains used the same culture medium, i.e., RPMI1640 culture medium containing 10% fetal bovine serum and 1% double antibody (penicillin and steptomycin).
- Cell survival rate (OD value of test group/OD value of control group) ⁇ 100%.
- test steps could also refer to YANG Xiuwei, et al., “Screening for antitumor activities of strychnos alkaloids in vitro”, Journal of Modern Chinese Medicine, 2006, 8(9): 11-13.
- the compound of Formula II had inhibition effect on growth of mice hepatoma cell line H22, and exhibited a concentration-effect relationship. Its IC 50 value was about 50 ⁇ g/mL, which suggested that this compound had good inhibition effect on proliferation of mice hepatoma cells.
- the compound of Formula II had inhibition effect on growth of human hepatoma cell line Hep22, and exhibited a concentration-effect relationship. Its IC 50 value was about 200 ⁇ g/mL, which suggested that this compound had good inhibition effect on proliferation of human hepatoma cells.
- the compound of Formula II had inhibition effect on growth of mice lymphoma cell YAC-1, and exhibited a concentration-effect relationship. Its IC 50 value was about 62.5 ⁇ g/mL, which suggested that this compound had good inhibition effect on proliferation of mice lymphoma cells.
- the compound of Formula II had inhibition effect on growth of human mononuclear lymphoma cell THP1, and exhibited a concentration-effect relationship. Its IC 50 value was about 250 ⁇ g/mL, which suggested that this compound had good inhibition effect on proliferation of human mononuclear lymphoma cells.
- FIG. 6 shows that the compound of Formula II had inhibition effect on growth of human mononuclear lymphoma cell THP1, and exhibited a concentration-effect relationship. Its IC 50 value was about 250 ⁇ g/mL, which suggested that this compound had good inhibition effect on proliferation of human mononuclear lymphoma cells.
- FIG. 6 shows that this compound had good inhibition effect on proliferation of human mononuclear lymphoma cells.
- the compound of Formula II had inhibition effect on growth of human tissue lymphoma cell U937, and exhibited a concentration-effect relationship. Its IC 50 value was about 50 ⁇ g/mL, which suggested that this compound had good inhibition effect on proliferation of human tissue lymphoma cells.
- the compound of the present invention especially compound of Formula II, had effective inhibition effects on many kinds of tumor cells, and was a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of cancers.
- ester derivatives or ether derivatives of compound of Formula II for example, “tetraacetate of compound of Formula II”, “tetra-p-tolylsulfonate of compound of Formula II”, “tetra(trifluoromethyl sulfonate) of compound of Formula II” and “tetra(tert-butyl-dimethyl-silyl ether) of compound of Formula II” as prepared in Examples 6-9 also had similar activity of inhibiting tumor cells, and were potential drugs for prophylaxis and/or treatment and/or adjunctive treatment of cancers.
- Porcine pancreatic lipase purchased from Sigma.
- Oleic acid purchased from Sigma.
- Enzyme solution was 0.5 mg/mL pancreatic lipase solution; buffer solution was 0.07M NaH 2 PO 4 —K 2 HPO 4 phosphate buffer solution (pH 7.0); color developing agent was 5% copper acetate solution, which was regulated with pyridine to have pH 6.1.
- the solutions were transferred to centrifuge tube, centrifuged under 4000 rpm for 10 minutes, and the organic phase and water phase were layered and clarified. 4 mL of the upper layer organic phase was taken and placed in a small conical flask, added with 1 mL of color developing agent, stirred with magnetic stirrer for 3 minutes, the generated oleic acid reacted with copper ions to form green complex compound. After centrifugation under 4000 rpm for 10 minutes, the upper layer of toluene solution containing copper oleate was taken, and measured with a spectrophotometer at 714 nm to determine its light absorbance. A blank solution without lipase was prepared as control by the same method, and concentration of fatty acid could be determined by referring to light absorbance working curve of oleic acid.
- Enzyme activity unit of lipase was defined as follows: an enzyme amount to release 1 ⁇ mol fatty acid under certain condition was defined as 1 unit of lipase activity (U).
- X represents enzyme activity of lipase, U/mL
- c represents concentration of fatty acid, ⁇ mol/mL
- V represents volume of fatty acid solution, mL
- V′ represents amount of enzyme solution, mL
- t represents action time, minute.
- Inhibition rate [(enzyme activity of lipase ⁇ enzyme activity of lipase after inhibition)/enzyme activity of lipase] ⁇ 100%
- the test results showed that the compound of the present invention, especially the compound of Formula II, had good inhibition effect on activity of lipase, had a IC 50 value of about 220 ⁇ g/mL, and exhibited concentration-effect relationship in inhibition effect. It could be seen that the compounds of the present invention were potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
- ester derivatives or ether derivatives of compound of Formula II for example, “tetraacetate of compound of Formula II”, “tetra-p-tolylsulfonate of compound of Formula II”, “tetra(trifluoromethyl sulfonate) of compound of Formula II” and “tetra(tert-butyl-dimethyl-silyl ether) of compound of Formula II” as prepared in Examples 6-9 also had similar activity of inhibiting lipase, and were potential drugs for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ═O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ═O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.
Description
- The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof.
- Monascus-fermented rice is a purple red rice koji prepared by using rice as raw material via fermentation with Monascus. Monascus-fermented rice is also called Danqu () in ancient China, which is obtained via fermentation in which koji or mold culture with Monascus as main component is cultured on cooked rice; it is red color, and thus is also called as red koji, red rice, or red wine dreg; and it is also called Fujian koji, Fujian rice, etc., because it is primarily produced in Fujian.
- China has a long history of utilizing Monascus, and it has been used for koji making since Han Dynasty. Monascus-fermented rice is a traditional Chinese medicine as both food and drug. It had been widely used for food coloring, wine-making, fermentation, Chinese medicine as early as in ancient times. <Principle of Correct Diet> () has the recordation that Monascus-fermented rice is of “sweet taste and neutral nature and smooth in taste, non-toxic” and “invigorating spleen, supplementing Qi, warming spleen and stomach”; <Compendium of Materia Medica> () has the recordation of “sweet, warm, non-toxic”, “capable of treating dysmenorrheal, extravasated blood after delivery, by grinding with rice wine and then drinking”; <Addendum for Amplification on Materia Medica> ( ) has recordation of “activating blood, helping digestion, invigorating spleen and warming stomach, capable of treating red and white vaginal discharge and diarrhea, as well as traumatic injury”.
- Since 1970s, when Prof. Endo of Japan firstly separated from red Monascus (Monascus ruber) a physiologically active substance, monacolin K, many researchers home and abroad discovered continually from Monascus metabolite other physiologically active substances, including monacolin compounds, Monascus pigment, pressure releasing component GABA and antioxidant component dimerumic acid, and some terpenoids being separated recently. With the development of modern biochemistry and pharmacology, functions of Monascus-fermented rice such as hypolipemic, lowering blood pressure, hyperglycemic, anti-obesity, anticancer, prophylaxis and treatment of senile dementia and osteoporosis are continuously revealed, which add more connotations to traditional Monascus-fermented rice.
- “Xuezhikang” capsules are an efficient, safe and modern Chinese medicine for lipid regulation which is prepared by Monascus fermentation and developed by Beijing Peking University WBL Biotechnology Co., Ltd. It is useful in treatment of indications such as cardiovascular and cerebrovascular diseases caused by hyperlipemia and atherosclerosis. Its action mechanism is of inhibiting endogenous cholesterol synthesis, reducing serum total cholesterol (TC), blood triglyceride (TG), low density lipoprotein (LDL) and elevating high density lipoprotein (HDL) level via inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA). Xuezhikang capsules are of an alcohol extract of Monascus-fermented rice, which are rich in a series of natural statins. Besides statins, Xuezhikang capsules further contain pigment, isoflavone, sterol, 20 kinds of amino acids, unsaturated fatty acids, and many trace elements. Thus, it is still in need to find novel compounds capable of lowering lipid or inhibiting HMG-CoA reductase activity.
- In addition, Xuezhikang may further comprise some unknown anticancer ingredients. Thus, it is also in need to find novel anticancer compounds.
- Obesity is a universal internal secretion metabolic disease, and intends to be wide-spread worldwide. It not only affects posture and activity, but also is closely associated with hyperlipemia, atherosclerosis, coronary heart disease, diabetes and so on. The occurrence of obesity relates to many factors, such as genetic factors, environmental factors, dietary habits, among which high fat diet is an important factor of obesity. In recent years, drug therapy is an effective means for treatment of obesity, which its therapeutic goal is usually achieved by reducing fat absorption. Lipases of pancreas and stomach are necessary for digestion and absorption of fats in intestinal tract. After fats in food are hydrolyzed into monoacylglycerol and free fatty acid, they are absorbed in intestinal tract, and then fats are synthesized again in vivo, causing fat accumulation, and finally resulting in obesity. Using lipase inhibitors can effectively inhibit decomposition and catalysis effects of lipases on fats in intestinal tract, so as to achieve the goal of reduction of fat absorption, control and treatment of obesity (CHEN Jin, etc., Advances in studying drug therapy of obesity, Chinese Archives of Traditional Chinese Medicine, 2007, 25(5):947-948; WU Jing, etc., Advances in drug therapy of obesity, Medical Recapitulate, 2006, 12(11):693-693).
- At present, only 2 drugs have been approved by FDA of US for long-term treatment of obesity: sibutramin (weight-reducing aid acting on central nervous) and orlistat (lipase inhibitor in gastrointestinal tract). However, both of the two drugs have significant adverse reactions: sibutramin has side-effects mainly including thirst, astriction, dizziness and insomnia, while orlistat has adverse reactions mainly including gastrointestinal symptoms, such as diarrhea, bellyache, oily flecks, flatulence, etc., and their long-term effects should be further evaluated.
- Thus, it is still in need at present to find novel drugs having function of inhibiting lipase.
- With a lot of experiments and inventive work, the inventors of the present invention obtain a new sterol derivative, and the inventors surprisingly find the compound of the present invention can effectively inhibit HMG-CoA reductase, and thus is a potential drug for reduction or regulation of blood-fat or prophylaxis and/or treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic. In addition, the inventors further surprisingly find that: 1) the compound of the present invention can effectively inhibit proliferation of cancer cells (tumor cells), and is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of cancers; 2) the compound of the present invention can effectively inhibit activity of lipase, and thus is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity. Thus, the following inventions are provided.
- One aspect of the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof,
- wherein,
- R1 is selected from the group consisting of —OH, ═O (carbonyl), H, and C1-C3 alkyl;
- R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl;
- R3 is selected from the group consisting of —OH, ═O, H, and C1-C3 alkyl;
- R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl;
- and none, one, two, three or four of R1, R2, R3, and R4 are —OH.
- As for the ester or ether of compound of Formula I, sites for forming the ester or ether are none, one, two, three or four of R1, R2, R3, and R4.
- In one embodiment of the present invention, R1 is —OH or ═O (carbonyl), R2, R3 and R4 are all H.
- The compound or pharmaceutically acceptable salt, ester or ether of any one of items of the present invention, it is a compound of Formula II as follows, or a pharmaceutically acceptable salt, ester or ether thereof,
- The compound of Formula II has chemical name of: 16,22-epoxy-ergosta-5,7-dien-3,20,23,25-tetraol.
- In the compound or pharmaceutically acceptable salt, ester or ether of any one of items of the present invention, said ester is selected from the group consisting of formate, acetate, propionate and sulfonate; said ether is tert-butyl-dimethyl silyl ether; specifically, said sulfonate group is p-tolylsulfonate or trifluoromethylsulfonate.
- The present invention further relates to a hydrate or solvate of the compound of Formula I or the compound of Formula II.
- Another aspect of the present invention relates to a method for preparing the compound of Formula I or the compound of Formula II, comprising the following steps:
- 1) providing Monascus-fermented rice and/or alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules, which is a dry powder), performing ultrasonic extraction once or more times with one or more organic solvents selected from the group consisting of dichloromethane, ethyl acetate, acetone, methanol, ethanol in 2-6 times by volume, 20-40 minutes each time, combining the extracted solutions, removing solvent to obtain a refined extract;
- Optionally, the alcohol extract can be obtained by the following method: using 50%-100% ethanol or 50%-100% methanol in 2-6 times by volume as solvent to perform ultrasonic extraction once or more times, 20-40 minutes each time, combining extracted solutions, removing solvent to obtain the alcohol extract.
- Without being restricted by any theory, because Xuezhikang itself is an alcohol extract of Monascus-fermented rice, Monascus-fermented rice can be directly used as raw material, and extracting steps are substantively the same for obtain the content of Xuezhikang, but Monascus-fermented rice has a relatively lower content of the compound. The specific strains of Monascus-fermented rice are not specifically limited, but include any strains of Monascus. Xuezhikang capsules (e.g., those manufactured by Beijing Peking University WBL Biotechnology Co., Ltd.) are commercially available in hospitals or pharmacies.
- 2) loading the refined extract obtained in step 1) on a silica gel column for separation, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- 3) taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to C18 reversed phase chromatography, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence;
- 4) taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting the fractions of chromatographic peak at 9.2 minute; and
- 5) freeze-drying the product of step 4) to obtain a compound of Formula I or Formula II.
- The preparation method according to any one items of the present invention, meets any one or more of following items (1) to (9):
- (1) in step 1), said organic solvent is preferably dichloromethane;
- (2) in step 1), said ultrasonic extraction is performed for 3 times;
- (3) in step 1), the solvent is removed by concentration under reduced pressure;
- (4) in step 2), the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- (5) in step 3), the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- It is found by the inventors that all elution fractions of petroleum ether-ethyl acetate (50:50-25:75) contain the compound of the present invention.
- (6) in step 3), the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- (7) in step 4), the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- It is found by the inventors that all elution fractions of methanol-water (50:50-75:25) contain the compound of the present invention.
- (8) in step 4), the fractions of collected chromatographic peak at 9.2 minute are combined; and
- (9) in step 5), the conditions for freeze-drying are: cold trap temperature is −40° C. to −85° C., vacuum degree is 0-100 Pa; preferably, cold trap temperature is −50° C. to −82.7° C., vacuum degree is 2-13 Pa; more preferably, cold trap temperature is −82.7° C., vacuum degree is 2 Pa, or cold trap temperature is −50° C., vacuum degree is 8.5 Pa.
- Further another aspect of the present invention relates to a method for preparing a compound of Formula II, comprising the following steps:
- using hexahydroxyergosterol (e.g., 3,16,20,22,23,25-hexahydroxy-ergosterol, briefly called as Compound A) as substrate, dehydrating in the presence of p-toluenesulfonic acid monohydrate or 2,4,6-triisopropylsulfonyl chloride to generate a compound of Formula II:
- The Compound A can be prepared by referring to the preparation method of Chinese Patent Publication CN101469014A (application number is 200710304346.0).
- In one embodiment of the present invention, the molar ratio of Compound A to p-toluenesulfonic acid monohydrate is 5:1-2:1; specifically, Compound A and p-toluenesulfonic acid monohydrate in toluene solution react under refluxing for 5-10 hours to obtain the compound of Formula II.
- In one embodiment of the present invention, the molar ratio of Compound A to 2,4,6-triisopropylsulfonyl chloride is 5:1 to 2:1; specifically, Compound A and 2,4,6-triisopropylsulfonyl chloride in pyridine solution react at a temperature of 30° C. to 70° C. for 10 to 30 hours to obtain the compound of Formula II.
- The compound of Formula II under certain conditions can generate different derivatives, such as ester derivatives, including but not being limited to acetate, sulfonate.
- The ester derivatives can be prepared by reacting a compound of Formula II with a common anhydride, acyl chloride, sulfonyl chloride, sulfonic acid. A catalyst useful in reaction with anhydride can be selected from pyridine, concentrated sulfuric acid, NaHCO3, etc. For examples:
- Tetraacetate of compound of Formula II (corresponding to a compound of Formula I, in which R1═R2═R3═R4═—OC(═O)—CH3) is prepared by: reacting a compound of Formula II with acetic anhydride as reaction agent and solvent in the presence of a catalytic amount of concentrated sulfonic acid at 40-80° C. for 1-3 hours.
- Tetra-p-tolylsulfonate of compound of Formula II (corresponding to a compound of Formula I, in which R1═R2═R3═R4═—OTs) is prepared by: reacting a compound of Formula II with p-toluenesulfonyl chloride in molar ratio of 1:4 to 1:8 in dichloromethane at 20-40° C. in the presence of triethylamine as acid scavenging agent.
- Tetra(trifluoromethylsulfonate) of compound of Formula II (corresponding to a compound of Formula I, in which R1═R2═R3═R4═CF3SO3—) is prepared by: reacting a compound of Formula II with trifluoromethanesulfonic anhydride in molar ratio of 1:4 to 1:6 in dichloromethane at 20-30° C. in the presence of pyridine for 1-5 hours.
- A compound of Formula II under certain conditions can also form silyl ether derivative, such as tert-butyl-dimethyl silyl ether of compound of Formula II. For example:
- Tetra(tert-butyl-dimethyl silyl ether) of compound of Formula II (corresponding to a compound of Formula I, in which R1═R2═R3═R4═TBDMSO—) is prepared by: reacting a compound of Formula II with sodium hydride in molar ratio of 1:4 in tetrahydrofuran, then reacting with tert-butyl-dimethylchlorosilane at 20-40° C. for 1-3 hours.
- Further another aspect of the present invention relates to an extract, which comprises a compound of Formula II of the present invention.
- The extract according to any one of items of the present invention is an extract of dry powder of content of Xuezhikang capsules or an extract of Monascus-fermented rice.
- In the extract according to any one of items of the present invention, the compound of Formula II has a content of 0.0001-5% (w/w), 0.001-2% (w/w) or 0.001-1% (w/w). The content of compound of Formula II can be regulated by appropriate concentration of the extract of the present invention. The concentration can be performed by a common method known by those skilled in the art.
- The extract according to any one of items of the present invention is any one of following (1) to (3):
- (1) the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the above steps 1) to 2); preferably, the elution fraction of ((50:50 or 25:75); further preferably, the elution fraction of petroleum ether-ethyl acetate (25:75).
- (2) the elution fraction of methanol-water (50:50-75:25) as prepared in the above steps 1) to 3); preferably, the elution fraction of methanol-water (75:25); and
- (3) the fractions of chromatographic peak at 9.2 minute as prepared in the above steps 1) to 4).
- Further another aspect of the present invention relates to a composition, which comprises a compound of Formula I or Formula II, and/or the extract of any one of items of the present invention; optionally, further comprises a pharmaceutically acceptable carrier or excipient. Specifically, the composition is a pharmaceutical composition.
- Usually, the pharmaceutical composition of the present invention comprises 0.1-90 wt % of a compound of Formula I or Formula II and/or pharmaceutically acceptable salt thereof. The pharmaceutical composition can be prepared according to a known method in the art. If necessary, the compound of Formula I or Formula II and/or pharmaceutically acceptable salt thereof can be combined with one or more solid or liquid pharmaceutically acceptable excipients and/or adjuvants to obtain a suitable administration form or dosage form.
- The compound of Formula I or Formula II or pharmaceutically acceptable salt thereof or pharmaceutical composition comprising it of the present invention can be administrated in unit dosage form, and administration route can be intestinal administration or parenteral administration, such as oral, muscle, subcutaneous, nasal, mouth mucosa, skin, peritoneum, or rectum administration. Administration dosage form can be, for example, tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, and lyophilized powder injections. They can be normal preparations, sustained-release preparations, controlled-release preparations and various particulate delivery systems. In order to prepare tablets as unit dosage form for administration, various carriers known in the art can be widely used. Examples of carrier are, for example, diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binding agents, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia mucilage, gelatin mucilage, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone; disintegrants, such as dry starch, alginates, agar powders, laminarin, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid esters, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose; disintegration inhibitors, such as sucrose, tristearin, cocoa butter, hydrogenated oil; absorption enhancers, such as quaternary ammonium salts, sodium dodecyl sulfate; lubricants, such as talc powders, silicon dioxide, corn starch, stearates, boric acid, liquid paraffin, polyethylene glycol. They can also be further processed to form coated tablets, such as sugar coated tablets, thin membrane coated tablets, enteric-coated tablets, or double-layer tablets or multiple-layer tablets. In order to prepare pills as administration unit, various carriers known in the art can be widely used. The example of carriers are, for example, diluents or absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc powder, etc.; binding agents, such as acacia gum, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrating agents, such as agar powder, dry starch, alginates, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc. In order to prepare suppositories as administration unit, various carriers known in the art can be widely used. The examples of carriers are, for example, polyethylene glycol, lecithin, cocoa butter, fatty alcohols, esters of fatty alcohols, gelatin, semi-synthesized glycerides, etc. In order to prepare capsules as administration unit, the compound of Formula I or Formula II or pharmaceutically acceptable salt thereof as effective ingredient is mixed with the above various carriers, and the obtained mixture is filled in hard gelatin capsules or soft capsules. The compound of Formula I or Formula II or pharmaceutically acceptable salt thereof as effective ingredient can also be processed to form microcapsules, then suspended in aqueous medium to form a suspension, or filled in hard capsules or processed to form an injection. In order to prepare injectable preparations as administration unit, for example, solutions, emulsions, lyophilized powder injections and suspensions, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, propane-1,3-diol, ethoxylated isostearyl alcohol, multiple-oxidized isostearyl alcohol, polyoxyethylene sorbitol fatty acid ester, etc. In addition, in order to prepare isotonic injection solutions, a suitable amount of sodium chloride, glucose or glycerol can be added to injection preparations, and conventional auxiliary solvents, buffers, pH regulators and so on can also be added.
- In addition, if necessary, coloring agents, preservatives, perfumes, correctants, sweetening agents or other materials can also be added to the pharmaceutical preparations.
- The dose of the compound of Formula I or Formula II or pharmaceutically acceptable salt thereof of the present invention depends on many factors, such as property and severity of the disease to be prevented or treated, patient's or animal's gender, age, bodyweight and individual reaction, the specific compound to be used, administration route, and administration frequency. The dose can be administered in single dose form or in several batches, such as 2-, 3- or 3-batches.
- The term “composition” in the text refers to a product comprising various components in designated amounts, and any product directly or indirectly derived from various components in designated amounts in combination.
- The actual dose levels of various active components in the pharmaceutical composition of the present invention can be changed so that the expected therapeutic effects can be achieved via the resultant amount relative to specific patient, composition and administration manner. The dose level must be selected according to the activity of the specific compound, administration route, severity of disease to be treated, patient's condition and medical history. However, the practice in the art is that the dose of compound gradually increases from a level lower than that for achieving the desired therapeutical effects to a dose capable of achieving the desired therapeutical effects.
- Further another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament for reduction or regulation of blood-fat or prophylaxis and/or treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic.
- Further another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a HMG-CoA reductase inhibitor.
- Further another aspect of the present invention relates to a method for inhibiting HMG-CoA reductase in vivo or in vitro, comprising the step of using an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention.
- The experimental results of Example 1 confirm that the compound of the present invention has activity of inhibiting HMG-CoA reductase, and the activity is dose dependent.
- Further another aspect of the present invention relates to a method for reduction or regulation of blood-fat or prophylaxis and/or treatment and/or adjunctive treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic, comprising the step of administering an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention.
- Further another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament for prophylaxis and/or treatment and/or adjunctive treatment of a cancer; specifically, said cancer is colon cancer, liver cancer, lymph cancer, or melanoma.
- Further another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament or an agent for inhibiting tumor cells; specifically, said tumor cells are colon cancer cells, liver cancer cells, lymph cancer cells, or melanoma cells.
- Further another aspect of the present invention relates to a method for inhibiting tumor cells, comprising the step of using an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention; specifically, said tumor cells are colon cancer cells, liver cancer cells, lymph cancer cells, or melanoma cells. Specifically, the method for inhibiting tumor cells is a method for inhibiting tumor cells in vitro or in vivo.
- The experimental results of Example 2 confirm the compound of the present invention can effectively inhibit tumor cells.
- Further another aspect of the present invention relates to a method for prophylaxis and/or treatment and/or adjunctive treatment of a cancer, comprising the step of using an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention; specifically, said cancer is colon cancer, liver cancer, lymph cancer, or melanoma.
- Further another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament or for prophylaxis and/or treatment and/or adjunctive treatment of obesity or a disease associated with obesity anti-obesity agent; specifically, said disease associated with obesity is hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- Further another aspect of the present invention relates to use of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention in the manufacture of a medicament or an agent for inhibiting lipase.
- Further another aspect of the present invention relates to a method for inhibiting lipase, comprising the step of using an effective amount of the compound of the present invention or the extract of any one of items of the present invention or the composition of the present invention. Specifically, said method for inhibiting lipase is a method for inhibiting lipase in vivo or in vitro.
- The experimental results of Example 3 confirm the compound of the present invention can effectively inhibit lipase.
- Further another aspect of the present invention relates to a method for prophylaxis and/or treatment and/or adjunctive treatment of obesity or a disease associated with obesity or a method for losing weight; specifically, said disease associated with obesity is hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- In the aforementioned treatment and/or prophylaxis and/or adjunctive treatment, a compound of the present invention in a therapeutically and/or prophylactically and/or adjunctively therapeutically effective amount can be used in form of pure compound, or in form of pharmaceutically acceptable esters or predrugs thereof (if they exist). Alternatively, the compound can be administered via a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients. It should be understood that the total amount per day of the compound or composition of the present invention must be determined by a physician within the range of reliable medical decisions. As for any specific patients, the specific therapeutically amount must be determined based on various factors, including the diseases to be treated and severity thereof, the activity of the used specific compound, the used specific composition, the age, body weight, general health status, gender and food of patient, the administration time and route and excretory rate of the used specific compound, the drug(s) administered in combination or simultaneously with the specific compound, and similar factors well known in the art of medicine. For example, it is a common method in the art to increase gradually the dose of compound from a level lower than that for achieving desired therapeutical effects to a level enough to achieve the desired therapeutical effects. In general, the dose of a compound of Formula I for mammals especially human can be 0.001-1000 mg/kg body weight per day, such as 0.01-100 mg/kg body weight per day, 0.01-10 mg/kg body weight per day.
- The compound according to the present invention can effectively prevent and/or treat the various diseases and disorders as mentioned in the present invention.
- In the present invention, the term “C1-C3 alkyl” comprises methyl, ethyl, propyl and isopropyl.
- The term “obesity” includes but is not limited to simple obesity (without a significant cause in internal secretion and metabolism, relating to heredity and feeding habits), secondary obesity (usually associating to some diseases such as hyperadrenocorticism, which could be eliminated when the diseases are cured). The obesity can be obesity in a mammal, and the mammal comprises human and pig.
- The term “disease associated with obesity” includes but is not limited to hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- The term lipase (enzyme classification number: EC3.1.1.3) includes but is not limited to a lipase of mammal, such as a lipase of human or a lipase of pig, the lipase of human can be human pancreatic lipase, and the lipase of pig can be porcine pancreatic lipase.
- The term “effective amount” refers to a dose that can fulfill treatment, prophylaxis and or remission of the diseases or disorders of the present invention in a subject.
- In the present invention, if not specifically described, a percentage content of an ingredient refers to a weight percentage (w/w).
- The present invention further relates to the following aspects 1 to 22:
- 1. Use of any one of items (1) to (4) in the manufacture of a medicament for prophylaxis and/or treatment and/or adjunctive treatment of a cancer; specifically, said cancer is colon cancer, liver cancer, lymph cancer, or melanoma,
- (1) a compound of Formula I or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is selected from the group consisting of —OH, ═O, H, and C1-C3 alkyl;
- R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl;
- R3 is selected from the group consisting of —OH, ═O, H, and C1-C3 alkyl;
- R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl;
- and 2, 3 or 4 of any of R1, R2, R3, and R4 are simultaneously —OH;
- (2) a compound of Formula II or a pharmaceutically acceptable salt
- thereof,
- (3) an extract, which comprises a compound of Formula II; and
- (4) a composition, which comprises any one of the above items (1)-(3).
- 2. Use of any one of items (1) to (4) of
Aspect 1 in the manufacture of a medicament or an agent for inhibiting tumor cells in vivo or in vitro; specifically, said tumor cells are colon cancer cells, liver cancer cells, lymph cancer cells, or melanoma cells. - 3. The use according to
Aspect 1 or 2, wherein the extract of item (3) is an extract of Monascus-fermented rice and/or an extract of an alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules). - 4. The use according to
Aspect 3, wherein the extract of item (3) is an elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the following steps 1) to 2); or an elution fraction of methanol-water (50:50-75:25) as prepared in the following steps 1) to 3); or fractions of chromatographic peak at 9.2 minute as prepared in the following steps 1) to 4): - 1) providing Monascus-fermented rice and/or alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules, which is a dry powder), performing ultrasonic extraction once or more times with one or more organic solvents selected from the group consisting of dichloromethane, ethyl acetate, acetone, methanol, ethanol in 2-6 times by volume, 20-40 minutes each time, combining the extracted solutions, removing solvent to obtain a refined extract;
- 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- 3) taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- 4) taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- 5. The use according to
Aspect 4, characterized in any one or more of items (1) to (8): - (1) in step 1), said organic solvent is dichloromethane;
- (2) in step 1), said ultrasonic extraction is performed for 3 times;
- (3) in step 1), the solvent is removed by concentration under reduced pressure;
- (4) in step 2), the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- (5) in step 3), the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- (6) in step 3), the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- (7) in step 4), the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- (8) in step 4), the fractions of collected chromatographic peak at 9.2 minute are combined.
- 6. The use according to
Aspect 1 or 2, wherein the composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient. - 7. A method for inhibiting tumor cells in vivo or in vitro, comprising the step of using an effective amount of any one of the items (1) to (4) of
Aspect 1; specifically, said tumor cells are colon cancer cells, liver cancer cells, lymph cancer cells, or melanoma cells. - 8. The method according to Aspect 7, wherein the extract of item (3) is an extract of Monascus-fermented rice and/or an extract of an alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules).
- 9. The method according to claim 8, wherein the extract of item (3) is the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the following steps 1) to 2); or the elution fraction of methanol-water (50:50-75:25) as prepared in the following steps 1) to 3); or fractions of chromatographic peak at 9.2 minute as prepared in the following steps 1) to 4):
- 1) providing Monascus-fermented rice and/or alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules, which is a dry powder), performing ultrasonic extraction once or more times with one or more organic solvents selected from the group consisting of dichloromethane, ethyl acetate, acetone, methanol, ethanol in 2-6 times by volume, 20-40 minutes each time, combining the extracted solutions, removing solvent to obtain a refined extract;
- 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- 3) taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- 4) taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- 10. The method according to Aspect 9, characterized in any one or more of items (1) to (8):
- (1) in step 1), said organic solvent is dichloromethane;
- (2) in step 1), said ultrasonic extraction is performed for 3 times;
- (3) in step 1), the solvent is removed by concentration under reduced pressure;
- (4) in step 2), the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- (5) in step 3), the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- (6) in step 3), the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- (7) in step 4), the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- (8) in step 4), the fractions of collected chromatographic peak at 9.2 minute are combined.
- 11. The method of Aspect 7, wherein the composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- 12. Use of any one of items (1) to (4) in the manufacture of a medicament for prophylaxis and/or treatment and/or adjunctive treatment of obesity or a disease associated with obesity or an anti-obesity agent; specifically, said disease associated with obesity is hyperlipidemia, atherosclerosis, coronary heart disease, or diabetes.
- (1) a compound of Formula I or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is selected from the group consisting of —OH, ═O, H, and C1-C3 alkyl;
- R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl;
- R3 is selected from the group consisting of —OH, ═O, H, and C1-C3 alkyl;
- R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl;
- and 2, 3 or 4 of any of R1, R2, R3, and R4 are simultaneously —OH;
- (2) a compound of Formula II or a pharmaceutically acceptable salt thereof,
- (3) an extract, which comprises a compound of Formula II; and
- (4) a composition, which comprises any one of the above items (1)-(3).
- 13. Use of any one of items (1) to (4) of Aspect 12 in the manufacture of a medicament or an agent for inhibiting lipase in vivo or in vitro.
- 14. The use according to Aspect 12 or 13, wherein the extract of item (3) is an extract of Monascus-fermented rice and/or an extract of an alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules).
- 15. The use according to Aspect 14, wherein the extract of item (3) is the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the following steps 1) to 2); or the elution fraction of methanol-water (50:50-75:25) as prepared in the following steps 1) to 3); or fractions of chromatographic peak at 9.2 minute as prepared in the following steps 1) to 4):
- 1) providing Monascus-fermented rice and/or alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules, which is a dry powder), performing ultrasonic extraction once or more times with one or more organic solvents selected from the group consisting of dichloromethane, ethyl acetate, acetone, methanol, ethanol in 2-6 times by volume, 20-40 minutes each time, combining the extracted solutions, removing solvent to obtain a refined extract;
- 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- 3) taking the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- 4) taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- 16. The use according to Aspect 15, characterized in any one or more of items (1) to (8):
- (1) in step 1), said organic solvent is dichloromethane;
- (2) in step 1), said ultrasonic extraction is performed for 3 times;
- (3) in step 1), the solvent is removed by concentration under reduced pressure;
- (4) in step 2), the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- (5) in step 3), the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- (6) in step 3), the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- (7) in step 4), the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- (8) in step 4), the fractions of collected chromatographic peak at 9.2 minute are combined.
- 17. The use according to Aspect 12 or 13, wherein the composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- 18. A method for inhibiting lipase in vivo or in vitro, comprising a step of using an effective amount of any one of the items (1) to (4) of Aspect 12.
- 19. The method according to Aspect 18, wherein the extract of item (3) is an extract of Monascus-fermented rice and/or an extract of an alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules).
- 20. The method according to claim 19, wherein the extract of item (3) is the elution fraction of petroleum ether-ethyl acetate (50:50-25:75) as prepared in the following steps 1) to 2); or the elution fraction of methanol-water (50:50-75:25) as prepared in the following steps 1) to 3); or fractions of chromatographic peak at 9.2 minute as prepared in the following steps 1) to 4):
- 1) providing Monascus-fermented rice and/or alcohol extract of Monascus-fermented rice (e.g., content of Xuezhikang capsules, which is a dry powder), performing ultrasonic extraction once or more times with one or more organic solvents selected from the group consisting of dichloromethane, ethyl acetate, acetone, methanol, ethanol in 2-6 times by volume, 20-40 minutes each time, combining the extracted solutions, removing solvent to obtain a refined extract;
- 2) subjecting the refined extract obtained in step 1) to chromatography separation with a silica gel column, eluting in gradient manner with petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate is 75:25, 50:50-25:75, 0:100 in sequence;
- 3) taking then elution fraction of petroleum ether-ethyl acetate (50:50-25:75) of step 2), subjecting to chromatography separation with a C18 reversed column, using methanol-water for gradient elution, the volume ratio of methanol-water is 10:90, 50:50-75:25, 100:0 in sequence; and
- 4) taking the elution fraction of methanol-water (50:50-75:25) of step 3), subjecting to purification with semi-preparative high performance liquid chromatography using acetonitrile-0.2% acetic acid aqueous solution (45:55) as mobile phase, C18 semi-preparative column as stationary phase, and collecting fractions of chromatographic peak at 9.2 minute.
- 21. The method according to
Aspect 20, characterized in any one or more of items (1) to (8): - (1) in step 1), said organic solvent is dichloromethane;
- (2) in step 1), said ultrasonic extraction is performed for 3 times;
- (3) in step 1), the solvent is removed by concentration under reduced pressure;
- (4) in step 2), the volume ratio of petroleum ether-ethyl acetate is 75:25, 50:50, 25:75, 0:100 in sequence;
- (5) in step 3), the elution fraction of petroleum ether-ethyl acetate (50:50 or 25:75) of step 2) is taken;
- (6) in step 3), the volume ratio of methanol-water is 10:90, 50:50, 75:25, 100:0 in sequence;
- (7) in step 4), the elution fraction of methanol-water (50:50 or 75:25) of step 3) is taken;
- (8) in step 4), the fractions of collected chromatographic peak at 9.2 minute are combined.
- 22. The method of Aspect 18, wherein the composition of item (4) further comprises a pharmaceutically acceptable carrier or excipient.
- 1. The compound of the present invention can effectively inhibit HMG-CoA reductase, and has dose-dependent activity for inhibiting HMG-CoA reductase; so that it is a potential drug for reduction or regulation of blood-fat or for prophylaxis and/or treatment of dyslipidemia, hyperlipemia, hypercholesterolemia, or atherosclerotic.
- 2. The compound of the present invention can effectively inhibit the proliferation of cancer cells (tumor cells), and has inhibition activity in concentration-effect relation; so that it is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of cancers.
- 3. The compound of the present invention can effectively inhibit the activity of lipase, and has inhibition activity in concentration-effect relation; so that it is a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
-
FIG. 1 : inhibition curve of a compound of Formula II on growth of HCT116 cells. -
FIG. 2 : inhibition curve of a compound of Formula II on growth of H22 cells. -
FIG. 3 : inhibition curve of a compound of Formula II on growth of HepG2 cells. -
FIG. 4 : inhibition curve of a compound of Formula II on growth of S180 cells. -
FIG. 5 : inhibition curve of a compound of Formula II on growth of YAC-1 cells. -
FIG. 6 : inhibition curve of a compound of Formula II on growth of THP1 cells. -
FIG. 7 : inhibition curve of a compound of Formula II on growth of U937 cells. -
FIG. 8 : inhibition curve of a compound of Formula II on growth of B16-F10 cells. -
FIG. 9 : absorbance working curve of oleic acid. - The present invention is further illustrated with the following examples, but those skilled in the art would understand the following examples are merely used to illustrate the present invention, rather than to limit the protection scope of the present invention. For those technologies or conditions not specifically described in the examples, they were performed according to the technologies or conditions as described in the documents in the art or according to the product specifications. For those reagents and instruments whose manufacturers were not given, they were all conventional products commercially available in markets.
- Operation Steps:
- 1) About 1 kg of dry powder of content of Xuezhikang capsules (produced by Beijing Peking University WBL Biotechnology Co., Ltd.) was provided, ultrasonic extraction was performed for 3 times with dichloromethane in 2-6 times by volume as solvent, 20-40 minutes for each time, all extracted solutions were combined, concentrated and subjected to solvent recovery under reduced pressure, to obtain 91 g of dichloromethane refined extract.
- 2) 50 g of the dichloromethane refined extract was loaded on silica gel column for chromatography separation, and eluted in gradient manner with petroleum ether and ethyl acetate. The volume ratio of petroleum ether-ethyl acetate was 75:25, 50:50, 25:75, 0:100 in sequence.
- 3) 5.0 g of fraction of petroleum ether-ethyl acetate (25:75) was taken, separated with C18 reversed column chromatography, eluted with methanol-water (10:90-100:0) in gradient manner to obtain 4 fractions (methanol-water 10: 90, 50: 50, 75: 25, 100: 0), in which 1.3 g of the elution fraction of methanol-water (75:25) was purified with semi-preparative high performance liquid chromatography, acetonitrile-0.2% acetic acid aqueous solution (45:55) was used as mobile phase, flow rate was 4 mL/min, C18 semi-preparative chromatography column (10×250 mm, 5 μm) was stationary phase, detection wavelength of DAD detector was 270 nm, chromatographic peaks at 9.2 minute were collected, accumulated for many times, then concentrated, freeze-dried to obtain about 40 mg of the compound.
- Operation Steps:
- 1) 5 kg of dry powder of Monascus-fermented rice was provided, ultrasonic extraction was performed for 3 times with dichloromethane in 2-6 times by volume as solvent, 20-40 minutes for each time, all extracted solutions were combined, concentrated and subjected to solvent recovery under reduced pressure, to obtain 78 g of dichloromethane refined extract.
- 2) 30 g of the dichloromethane refined extract was loaded on silica gel column for chromatography separation, and eluted in gradient manner with petroleum ether and ethyl acetate. The volume ratio of petroleum ether-ethyl acetate was 75:25, 50:50, 25:75, 0:100 in subsequence.
- 3) 3.0 g of fraction of petroleum ether-ethyl acetate (25:75) was taken, separated with C18 reversed column chromatography, eluted with methanol-water (10:90-100:0) in gradient manner to obtain 4 fractions (methanol-water 10:90, 50:50, 75:25, 100:0), in which 0.8 g of the elution fraction of methanol-water (75:25) was purified with semi-preparative high performance liquid chromatography, acetonitrile-0.2% acetic acid aqueous solution (45:55) was used as mobile phase, flow rate was 4 mL/min, C18 semi-preparative chromatography column (10×250 mm, 5 μm) was stationary phase, detection wavelength of DAD detector was 270 nm, chromatographic peaks at 9.2 minute were collected, accumulated for many times, then concentrated, freeze-dried to obtain about 25 mg of the compound.
- In a reaction flask, toluene (350mL) was added, then Compound A (4.4 g, 9.2 mmol) and p-toluenesulfonic acid monohydrate (0.59 g, 3.1 mmol) were added, heated to refluxing and water was removed by azeotropism for 7 hours, cooled to room temperature after reaction, solvent was removed under reduced pressure, then silica gel column chromatograph was performed for purification, to obtain a sticky oily compound, i.e., compound of Formula II.
- In a reaction flask, pyridine (100 mL) was added, then Compound A (4.4 g, 9.2 mmol) and 2,4,6-triisopropylsulfonyl chloride (0.93 g, 3.1 mmol) were added, heated and reacted at 50° C. for 20 hours, solvent was removed under reduced pressure, then silica gel column chromatograph was performed for purification, to obtain a sticky oily compound, i.e., compound of Formula II.
- The samples used were compounds prepared in Examples 1, 2, 3, 4. The results confirmed that all compounds prepared in Examples 1-4 were the same, i.e., compound of Formula II.
- 1. Physical and Chemical Data of Compounds
- White powder, optical rotation: [α]25 D−50.00 (c 0.118, CH2Cl2:MeOH=1:1);
- UV spectrum showed 3 maximum absorption peaks, separately, λmax(CH2Cl2:MeOH)=271.6 nm, 282.2 nm, 293.8 nm.
- FT-IR (KBr, cm−1) spectrum: 3392(—OH), 2969, 2933 (saturated hydrocarbon), 1652, 1647(C═C), 1456, 1378 (gem-dimethyl).
- 2. Determination of Molecular Formula
- HR-ESI-MS gave m/z 483.3104 [M+Na]+ (calcd. 483.3081, err 2.3), so that the molecular weight of the compound was deduced as 460.32. 1H-NMR and 13C-NMR showed that there were 40 hydrogen signals and 28 carbon signals. DEPT showed there were 6 quaternary carbons, 10 CH, 6 CH2 and 6 CH3. In 13C-NMR, 4 olefinic carbon signals were at 117.2 ppm, 119.6 ppm, 139.1 ppm and 140.6 ppm. The analysis of combining HSQC and 13C-NMR showed there were 6 oxygenated carbons linked to oxygen atoms at 70.5 ppm, 72.4 ppm, 74.5 ppm, 80.4 ppm, 83.8 ppm and 84.4 ppm. In view of molecular weight with 1H, 13C-NMR and DEPT spectra in combination, if the compound had 6 oxygen atoms, its molecular weight would exceed 460.32, thus it could be deduced that the compound should have 5 oxygen atoms and 4 hydrogen atoms that did not present signals in 1H-NMR spectrum. Thus, among the above 5 oxygen atoms, 4 oxygen atoms belonged to 4 hydroxyls, while the 5th oxygen existed in form of ether. According to the above analysis, it could be determined that the molecule had 28 carbon atoms, 44 hydrogen atoms, and 5 oxygen atoms, and the molecular formula was C28H44O5.
- 3. Determination of the Chemical Structure
- By analyzing the 13C-NMR and DEPT spectra of the compound, there were 28 carbon atoms, in which 6 carbon atoms were of methyl forms. Since 3 maximum absorption peaks at 271.6 nm, 282.2 nm and 293.8 nm in UV spectrum were substantively identical to those of ergosterol, it was primarily determined that the compound had framework of ergosterol. Its unsaturation degree was 7 based on calculation of molecular formula. Thus, it could be deduced that, besides 6 degrees of unsaturation including 2 double bonds and 4 rings of ergosterol framework, the compound further had one degree of unsaturation and it must be a ring, so that this ring could be determined as an epoxy formed with the 5th oxygen atom as center. The HSQC and HMBC spectra were analyzed in combination and showed that the 6 carbon atoms linked to oxygen atoms were separately assigned to 4 carbon atoms linked to 4 hydroxyls (70.5, 72.4, 74.5, 80.4 ppm) and 2 carbon atoms linked to the residual one oxygen atom (83.8, 84.4 ppm). Deep analysis of HMBC spectra showed that the 5th ring system was a 5-membered ring consisting of C-16 (83.8 ppm), C-17 (66.9 ppm), C-20 (80.4 ppm), C-22 (84.4 ppm) and oxygen atom. This satisfied degree of unsaturation and number of carbon atoms linked to oxygen atoms. Further analysis of mass spectrum gave molecular weight and molecular formula, which confirmed the above analysis. In sum, the above analysis indicated that the new compound was: 16,22-epoxy-ergosta-5,7-dien-3,20,23,25-tetraol. The chemical structure was shown in the following Formula II:
- 4. NMR Data of Compound of Formula II
- The data were shown in Table 1.
-
TABLE 1 NMR data of compound of Formula II (600 MHz, CDCI3, J in Hz) 1H-NMR, 13C-NMR, HMBC No. (ppm) (ppm) DEPT (H→C) 1 1.28 (1H, m) 38.4 CH2 — 1.90 (1H, m) 2 1.48 (1H, m) 32.1 CH2 — 1.89 (1H, m) 3 3.62 (1H, m) 70.5 CH — 4 2.39 (1H, m) 40.9 CH2 — 2.46 (1H, m) 5 — 140.6 C — 6 5.56 (1H, m) 119.6 CH 4, 7 7 5.38 (1H, m) 117.2 CH — 8 — 139.1 C — 9 1.95 (1H, m) 46.0 CH — 10 — 37.3 C — 11 1.60 (1H, m) 20.8 CH2 — 1.77 (1H, m) 12 1.25 (1H, m) 39.3 CH2 — 2.08 (1H, m) 13 — 43.0 C 14 1.87 (1H, m) 54.0 CH 13 15 1.75 (1H, m) 34.2 CH2 14 2.23 (1H, m) 16 4.66 (1H, m) 83.8 CH 13, 14, 15 17 1.90 (1H, m) 66.9 CH 20, 22 18 1.12 (3H, s) 14.6 CH3 27, 12, 13, 14 19 0.96 (3H, s) 16.6 CH3 9, 10, 1 20 — 80.4 C — 21 1.43 (3H, s) 27.8 CH3 20, 22, 24 22 4.19 (1H, brs) 84.4 CH 21, 24, 23, 20 23 3.66 (1H, brd, 72.4 CH 28, 24, 25, 20 J = 9.0 Hz) 24 1.75 (1H, m) 46.4 CH 27, 28 25 — 74.5 C — 26 1.20 (3H, s) 30.3 CH3 25, 24 27 1.23 (3H, s) 24.0 CH3 25, 24 28 0.82 (3H, d, 14.0 CH3 23, 25, 24 J = 7.2 Hz) Notation: “—” represents concern signal does not exist. - The mixture of Compound A (4.23 g, 9.2 mmol) and 2 drops of concentrated sulfuric acid in 20 mL of acetic anhydride was heated with water-bath to 50° C., reacted for 2 hours, cooled, added with saturated NaHCO3 aqueous solution, extracted with toluene for 3 times, the organic layer was evaporated under rotation to obtain a product, and further purified by silica gel column chromatography to obtain tetraacetate of compound of Formula II via silica gel column chromatography. Pyridine catalysis could be used for prevention of configuration reversion.
- In a dry 25 mL flask, compound of Formula II (4.23 g, 9.2 mmol) and 50 mL of dry dichloromethane were added, cooled to 0° C., p-tolylsulfonyl chloride (10.56 g, 55.3 mmol) was added, triethylamine (7.46 g, 73.6 mmol) was added dropwise under stirring. After end of dropwise adding, the reaction mixture solution was stirred at 20° C. for 1 hour, washed with water (50 mL×3), dried with anhydrous sodium sulfate, filtrated, dried out solvent by evaporation to obtain a crude product, and subjected to rapid column chromatography to obtain tetra-p-tolylsulfonate of compound of Formula II.
- Compound of Formula II (4.23 g, 9.2 mmol) and pyridine (4.36 g, 55.2 mmol) were added in sequence into a flask containing 50 mL of dry dichloromethane under stirring, then trifluoromethylsulfonate (12.46 g, 44.2 mmol) was slowly added dropwise at room temperature (25° C.) within about 20 minutes, reacted for 2 hours, concentrated filtrate, the residue was subjected to separation with silica gel column chromatography to obtain tetra(trifluoromethylsulfonate) of compound of Formula II.
- In a 100 mL round bottom flask, 20 mL of THF and 1.26 g of NaH (content: 70%, 36.8 mmol) wrapped with mineral oil were added, stirred to sufficiently disperse NaH, added dropwise with compound of Formula II (4.23 g, 9.2 mmol) in THF (10 mL), reacted at room temperature under vigorous agitation for 1 hour. TBDMS-C1 (tert-butyldimethylchlorosilane) (5.53 g, 36.8 mmol) was dissolved in 10 mL THF, added dropwise to the above reaction solution under stirring, the speed of dropwise adding was controlled so that the reaction temperature was not extremely high, after end of dropwise adding, the reaction was continued at room temperature under stirring for 1.5 hours. The reaction solution was poured in water, extracted with dichloromethane; the organic phase was washed with water to neutrality, washed with saturated brine, dried with anhydrous sodium sulfate. The filtrate was concentrated, separated with column chromatography, to obtain tetra (tert-butyl-dimethyl-silyl ether) of compound of Formula II.
- 1. Test Materials
- 1.1 Drugs
- Compound of Formula II—prepared in Examples 1-4.
- Standard sample of lovastatin—purchased from Sigma.
- 1.2 Enzymes
- Rat liver microsomes (HMG-CoA reductase)—, could be commercially available or prepared by the following preparation method: taking out liver of male rat, washing with KESD buffer solution, centrifuging under 1200 g for 15 minutes, collecting supernatant, then centrifuging under 105,000 g twice, 90 minutes for each time, and collecting centrifugation deposit. The centrifugation deposit was added with 8.3% of glycerol, heated with 37° C. bath for 1 hour. The crude product of rat liver microsomes was purified with saturated ammonium sulfate, and 35-50% of purified fraction was collected. The purified fraction obtained could be stored in −80° C. refrigerator.
- 1.3 Reagents
- Potassium chloride, potassium dihydrogen phosphate, ethylenediamine tetraacetic acid, dithiothreitol—purchased from Beijing Chemical Reagents Co., Ltd.;
- Nicotinamide adenine dinucleotide (NADPH)—purchased from Merk;
- 3-hydroxy-3-methylglutary coenzyme A (HMG-CoA)—purchased from Sigma.
- 2. Test Methods
- Compound of Formula II was dissolved in 75% ethanol solution, with initial concentration of 8.0 mg/mL, and diluted in gradient manner, to reach 4.0 mg/mL, 2.0 mg/mL, 1.0 mg/mL; lovastatin was used as positive control, dissolved with 75% ethanol solution to reach concentration of 2.0 mg/mL; in the test system, total volume was 250 μL, concentrations of ingredients were separately:
potassium chloride 200 mM, potassium dihydrogen phosphate 160 mM, ethylenediaminetetraacetic acid 4 mM, dithiothreitol 10 mM, nicotinamide adenine dinucleotide and 3-hydroxy-3-methylglutary coenzyme A as two substrates separately had concentrations of: 200 μM and 50 μM, pH6.8, 30 μL of enzyme was added, 4 test groups were separately added with 10 μL of new compound solutions with different concentrations, the positive control group was added with 10 μL of lovastatin solution, the blank control group was added with 10 μL of 75% ethanol solution, and dynamitic changes of OD340 were detected with Versamax ELISA at 37° C. condition. The rate of decline of OD340 (expressed in slope value) as detected within 5 minutes was used to evaluate the activity of HMG-CoA reductase, and then to evaluate the activity of enzyme inhibitor and the results were shown in Table 2. - 3. Test Results
- The results were shown in Table 2.
-
TABLE 2 Test results of activity of enzyme inhibitors Inhibitor Final Inhibi- concen- Inhibitor concentration tion tration volume in system rate Sample name (mg/mL) (μL) (μg/mL) Slope (%) Blank control — — — 16.0 — Lovastatin 2.0 10 80 7.3 54.4 Compound of 8.0 10 320 7.5 53.1 Formula II 4.0 10 160 8.7 45.6 2.0 10 80 11.3 29.4 1.0 10 40 13.7 14.4 * Blank control was solvent; Lovastatin was positive control. - The test results showed that the compound of the present invention, especially, the compound of Formula II, had inhibition effect on activity of HMG-CoA reductase, and presented concentration-effect relationship. Its IC50 value was about 250 μg/mL, which indicated that the compound has good inhibition effects on activity of HMG-CoA reductase.
- Further studying showed that the ester derivatives or ether derivatives of compound of Formula II, for example, “tetraacetate of compound of Formula II”, “tetra-p-tolylsulfonate of compound of Formula II”, “tetra(trifluoromethylsulfonate) of compound of Formula II” and “tetra(tert-butyl-dimethyl-silyl ether) of compound of Formula II” as prepared in Examples 6-9 also had similar activity of inhibiting HMG-CoA reductase.
- 1 Test Materials
- 1.1 Strains of Cells
- HCT116 and H22, purchased from Korean cell line bank, Seoul, Korea;
- S180, HepG-2, YAC-1, Thp1, U937 and B16-F10, purchased from the Cell Bank of the Committee on Type Culture Collection of Chinese Academy of Sciences.
- 1.2 Drugs
- New compound (compound of Formula II) prepared in Examples 1-4.
- 1.3 Reagents
- MTT was purchased from Amresco; RPMI1640 and double antibody were purchased from Sigma; fetal bovine serum (FBS) was purchased from Gibco in USA; all other reagents were of analytical purity and made in China.
- 2 Test Methods
- Cancer cells of exponential growth phase were inoculated on 96-well plate, 2×104 cells/well, added with drug until final drug concentrations were: 500, 250, 125, 62.5, 31.25, 15.625 and 7.8125 μg/mL, cultured at 37° C. in 5% CO2 cell culture incubator for 72 hours, then added with MTT, 10 μL/well, incubated in dark at 37° C. for 4 hours, culture medium was removed, 150 μL of DMSO or acidified isopropanol was added, vibrated for 5 minutes, and then OD values were measured under wavelength of 570 nm. This was repeated for 3 times, and a blank control was set. These cell strains used the same culture medium, i.e., RPMI1640 culture medium containing 10% fetal bovine serum and 1% double antibody (penicillin and steptomycin).
- Calculation Formula:
-
Cell survival rate=(OD value of test group/OD value of control group)×100%. - The test steps could also refer to YANG Xiuwei, et al., “Screening for antitumor activities of strychnos alkaloids in vitro”, Journal of Modern Chinese Medicine, 2006, 8(9): 11-13.
- 3 Test Results
- 3.1 Activity of Compound of Formula II Against Cancer (Colon Cancer) In Vitro
- The results were shown in
FIG. 1 . The results showed that the compound of Formula II had inhibition effect on growth of human colon cancer cell strain HCT116, and exhibited concentration-effect relationship. It could be seen that this compound had potency for prophylaxis and treatment of colon cancer. - 3.2 Activity of Compound of Formula II Against Cancer (Liver Cancer) In Vitro
- 3.2.1 As showing in
FIG. 2 , the compound of Formula II had inhibition effect on growth of mice hepatoma cell line H22, and exhibited a concentration-effect relationship. Its IC50 value was about 50 μg/mL, which suggested that this compound had good inhibition effect on proliferation of mice hepatoma cells. - 3.2.2 As showing in
FIG. 3 , the compound of Formula II had inhibition effect on growth of human hepatoma cell line Hep22, and exhibited a concentration-effect relationship. Its IC50 value was about 200 μg/mL, which suggested that this compound had good inhibition effect on proliferation of human hepatoma cells. - 3.2.3 As showing in
FIG. 4 , the compound of Formula II had inhibition effect on growth of mice sarcoma cell line S180, and exhibited a concentration-effect relationship. - It could be seen that this compound had potency for prophylaxis and treatment of liver cancer.
- 3.3 Activity of Compound of Formula II Against Cancer (Lymphoma) In Vitro
- 3.3.1 As showing in
FIG. 5 , the compound of Formula II had inhibition effect on growth of mice lymphoma cell YAC-1, and exhibited a concentration-effect relationship. Its IC50 value was about 62.5 μg/mL, which suggested that this compound had good inhibition effect on proliferation of mice lymphoma cells. - 3.3.2 As showing in
FIG. 6 , the compound of Formula II had inhibition effect on growth of human mononuclear lymphoma cell THP1, and exhibited a concentration-effect relationship. Its IC50 value was about 250 μg/mL, which suggested that this compound had good inhibition effect on proliferation of human mononuclear lymphoma cells.FIG. 6 . - 3.3.3 As showing in
FIG. 7 , the compound of Formula II had inhibition effect on growth of human tissue lymphoma cell U937, and exhibited a concentration-effect relationship. Its IC50 value was about 50 μg/mL, which suggested that this compound had good inhibition effect on proliferation of human tissue lymphoma cells. - It could be seen that this compound had potency for prophylaxis and treatment of lymph cancer (lymphoma).
- 3.4 Activity of Compound of Formula II Against Cancer (Melanoma) In Vitro
- The results were shown in
FIG. 8 . The results showed that the compound of Formula II had inhibition effect on growth of mice melanoma cell B16-F10, and exhibited concentration-effect relationship. Its IC50 value was about 62.5 μg/mL, which suggested that this compound had potency for prophylaxis and treatment of melanoma. - In sum, the compound of the present invention, especially compound of Formula II, had effective inhibition effects on many kinds of tumor cells, and was a potential drug for prophylaxis and/or treatment and/or adjunctive treatment of cancers.
- Further studying showed that the ester derivatives or ether derivatives of compound of Formula II, for example, “tetraacetate of compound of Formula II”, “tetra-p-tolylsulfonate of compound of Formula II”, “tetra(trifluoromethyl sulfonate) of compound of Formula II” and “tetra(tert-butyl-dimethyl-silyl ether) of compound of Formula II” as prepared in Examples 6-9 also had similar activity of inhibiting tumor cells, and were potential drugs for prophylaxis and/or treatment and/or adjunctive treatment of cancers.
- 1 Test Materials
- 1.1 Drugs
-
- Compound of Formula II.
- Orlistat—purchased from Golden Elephant Pharmacy.
- 1.2 Enzymes
- Porcine pancreatic lipase—purchased from Sigma.
- 1.3 Reagents
- Oleic acid—purchased from Sigma.
- Toluene, olive oil, pyridine, copper acetate, NaH2PO4, K2HPO4 were all of analytic purity and made in China.
- 2 Test Methods
- The steps were shown as follows, and could also refer to JIANG Huifang, WANG Yaqin, LIU Chunguo, Comparison and improvement of three methods for measurement of lipase activity, Journal of Chemistry & Bioengineering, 2007, 24(8):72-75; and ZHU Xiaoqing, LU Jingci, HUO Shixin, et al., Inhibitory Effect on Lipase of Alkaloid Derived from Lotus Leaf, Journal of Shanghai University (Natural Science), 2007, 13(1):85-87.
- 2.1 Preparation of light absorbance working curve for fatty acid: a series of oleic acid-toluene solutions with different concentrations (0-3.5 mmol/L, separately being 0, 0.225, 0.45, 0.675, 0.9, 1.125, 1.35, 1.8, 2.25, 2.7, and 3.5 mmol/L), 4 mL of each was taken and placed in conical flask, added with 1 mL of color developing agent, stirred with magnetic force for 3 minutes, oleic acid molecules and copper ions formed a green complex compound, after centrifugation, organic phase of upper layer was taken and measured at 714 nm to determine light absorbance.
- 2.2 Enzyme solution was 0.5 mg/mL pancreatic lipase solution; buffer solution was 0.07M NaH2PO4—K2HPO4 phosphate buffer solution (pH 7.0); color developing agent was 5% copper acetate solution, which was regulated with pyridine to have pH 6.1.
- 2.3 Measurement of Lipase Activity:
- 3 mL of 0.07M phosphate buffer solution and 1 mL of olive oil were pre-heated at a constant temperature of 37° C. for 5 minutes in water bath under agitation with a magnetic stirrer, added with 1.3 mL of enzyme solution (negative control was that without enzyme inhibitor; positive control is that added with 100 μL of 0.1 mg/mL orlistat solution; 0.6, 0.9, 1.1, 1.3, 1.8 mg/mL compound of Formula II solutions were added, each 100 μL), stirred with magnetic force for 10 minutes, immediately added with 8 mL of toluene, stirred continuously for 2 minutes, the reaction was terminated, the generated oleic acid was extracted. The solutions were transferred to centrifuge tube, centrifuged under 4000 rpm for 10 minutes, and the organic phase and water phase were layered and clarified. 4 mL of the upper layer organic phase was taken and placed in a small conical flask, added with 1 mL of color developing agent, stirred with magnetic stirrer for 3 minutes, the generated oleic acid reacted with copper ions to form green complex compound. After centrifugation under 4000 rpm for 10 minutes, the upper layer of toluene solution containing copper oleate was taken, and measured with a spectrophotometer at 714 nm to determine its light absorbance. A blank solution without lipase was prepared as control by the same method, and concentration of fatty acid could be determined by referring to light absorbance working curve of oleic acid.
- 3 Definition and Calculation Formula of Enzyme Activity
- Enzyme activity unit of lipase was defined as follows: an enzyme amount to release 1 μmol fatty acid under certain condition was defined as 1 unit of lipase activity (U).
- The following formula was used to calculate enzyme activity: X=(cV)/(tV′)
- wherein: X represents enzyme activity of lipase, U/mL; c represents concentration of fatty acid, μmol/mL; V represents volume of fatty acid solution, mL; V′ represents amount of enzyme solution, mL; t represents action time, minute.
-
Inhibition rate=[(enzyme activity of lipase−enzyme activity of lipase after inhibition)/enzyme activity of lipase]×100% - 4 Test Results
- 4.1 Light Absorbance Working Curve of Oleic Acid
- As shown in
FIG. 9 . - 4.2 Test Results of Activity of Enzyme Inhibitors
- As shown in following Table 3.
-
TABLE 3 Test results of activity of enzyme inhibitors Final concentration Concentration concentration of inhibitor in of generated Enzyme Inhibition of the inhibitor the system oleic acid activity rate Sample name (mg/mL) (μg/mL) Absorbance (mM) U/mL (%) Blank control — — 0.6680 2.75 1.69 — Orlistat 0.1 1.85 0.2042 0.81 0.50 69.84% Compound of 6 111 0.5665 2.32 1.43 15.38% Formula II 9 166 0.5035 2.06 1.27 24.85% 11 203 0.3998 1.63 1.00 40.83% 13 240 0.2743 1.10 0.68 59.76% 18 333 0.2611 1.04 0.64 62.13% - wherein the enzyme activity was calculated according to the calculation formula of the
above section 3, wherein: -
V=8 mL; V′=1.3 mL; t=10 minutes. - The test results showed that the compound of the present invention, especially the compound of Formula II, had good inhibition effect on activity of lipase, had a IC50 value of about 220 μg/mL, and exhibited concentration-effect relationship in inhibition effect. It could be seen that the compounds of the present invention were potential drug for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
- Further studying showed that the ester derivatives or ether derivatives of compound of Formula II, for example, “tetraacetate of compound of Formula II”, “tetra-p-tolylsulfonate of compound of Formula II”, “tetra(trifluoromethyl sulfonate) of compound of Formula II” and “tetra(tert-butyl-dimethyl-silyl ether) of compound of Formula II” as prepared in Examples 6-9 also had similar activity of inhibiting lipase, and were potential drugs for prophylaxis and/or treatment and/or adjunctive treatment of obesity or diseases associated with obesity.
- Although the specific embodiments of the present invention have been described in details, those skilled in the art would understand these details can be modified or substituted according to the disclosed teachings, and all these changes are within the protection scope of the present invention. The whole scope of the present invention is defined by the appending claims.
- This application is a divisional application of U.S. patent application Ser. No. 17/071,963, filed Oct. 15, 2020, which is a divisional application of U.S. patent application Ser. No. 14/368,494, filed Jun. 24, 2014, issued as U.S. Pat. No. 10,889,612, which is a 371 national stage application of International Patent Application No. PCT/CN2012/087360, filed Dec. 25, 2012, which claims the benefit of Chinese Patent Application No. 201110441993.2, filed Dec. 26, 2011, and Chinese Patent Application No. 201110442009.4, filed Dec. 26, 2011, and Chinese Patent Application No. 201210015475.9, filed Jan. 18, 2012, which applications are incorporated herein by reference in their entirety.
Claims (4)
2. The extract of claim 1 , wherein the compound of Formula II is present in the dry powder of content of Xuezhikang capsules or Monascus-fermented rice at an amount of 0.0001-5% (w/w).
3. The extract of claim 1 , wherein the compound of Formula II is present in the dry powder of content of Xuezhikang capsules or Monascus-fermented rice at an amount of 0.001-2% (w/w).
4. The extract of claim 1 , wherein the compound of Formula II is present in the dry powder of content of Xuezhikang capsules or Monascus-fermented rice at an amount 0.001-1% (w/w).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/820,553 US20220402967A1 (en) | 2011-12-26 | 2022-08-17 | Sterol derivatives and preparation method and uses thereof |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110442009.4 | 2011-12-26 | ||
CN201110442009.4A CN103169713B (en) | 2011-12-26 | 2011-12-26 | A kind of sterol derivative is preparing the purposes in cancer therapy drug |
CN201110441993.2A CN103172693B (en) | 2011-12-26 | 2011-12-26 | A kind of sterol derivative, Preparation Method And The Use |
CN201110441993.2 | 2011-12-26 | ||
CN201210015475.9A CN103211822B (en) | 2012-01-18 | 2012-01-18 | A kind of purposes of the suppression lipase of sterol derivative |
CN201210015475.9 | 2012-01-18 | ||
PCT/CN2012/087360 WO2013097681A1 (en) | 2011-12-26 | 2012-12-25 | Sterols derivative, and preparation method and purpose thereof |
US201414368494A | 2014-06-24 | 2014-06-24 | |
US17/071,963 US11634454B2 (en) | 2011-12-26 | 2020-10-15 | Sterol derivatives and preparation method and uses thereof |
US17/820,553 US20220402967A1 (en) | 2011-12-26 | 2022-08-17 | Sterol derivatives and preparation method and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/071,963 Division US11634454B2 (en) | 2011-12-26 | 2020-10-15 | Sterol derivatives and preparation method and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220402967A1 true US20220402967A1 (en) | 2022-12-22 |
Family
ID=48696334
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/368,494 Active US10889612B2 (en) | 2011-12-26 | 2012-12-25 | Sterol derivatives and preparation method and uses thereof |
US17/071,963 Active US11634454B2 (en) | 2011-12-26 | 2020-10-15 | Sterol derivatives and preparation method and uses thereof |
US17/071,958 Pending US20210024570A1 (en) | 2011-12-26 | 2020-10-15 | Sterol derivatives and preparation method and uses thereof |
US17/818,302 Active US11845774B2 (en) | 2011-12-26 | 2022-08-08 | Sterol derivatives and preparation method and uses thereof |
US17/818,667 Active US11845775B2 (en) | 2011-12-26 | 2022-08-09 | Sterol derivatives and preparation method and uses thereof |
US17/820,553 Pending US20220402967A1 (en) | 2011-12-26 | 2022-08-17 | Sterol derivatives and preparation method and uses thereof |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/368,494 Active US10889612B2 (en) | 2011-12-26 | 2012-12-25 | Sterol derivatives and preparation method and uses thereof |
US17/071,963 Active US11634454B2 (en) | 2011-12-26 | 2020-10-15 | Sterol derivatives and preparation method and uses thereof |
US17/071,958 Pending US20210024570A1 (en) | 2011-12-26 | 2020-10-15 | Sterol derivatives and preparation method and uses thereof |
US17/818,302 Active US11845774B2 (en) | 2011-12-26 | 2022-08-08 | Sterol derivatives and preparation method and uses thereof |
US17/818,667 Active US11845775B2 (en) | 2011-12-26 | 2022-08-09 | Sterol derivatives and preparation method and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (6) | US10889612B2 (en) |
EP (1) | EP2799444B1 (en) |
CN (1) | CN104024270B (en) |
ES (1) | ES2666459T3 (en) |
HK (1) | HK1198539A1 (en) |
MY (1) | MY172011A (en) |
SG (1) | SG11201403618PA (en) |
TW (1) | TWI518094B (en) |
WO (1) | WO2013097681A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI518094B (en) * | 2011-12-26 | 2016-01-21 | Univ Beijing Peking Wbl Biotech Co Ltd | One kind of derivatives of sterols, their preparation and use |
CN109371053B (en) * | 2018-12-24 | 2021-08-06 | 江西科技师范大学 | Construction method of monascus pigment producing strain |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046022A (en) * | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238348B2 (en) * | 1996-09-30 | 2007-07-03 | Beijing Peking University Wbl Corporation Ltd. | Method of treatment of osteoporosis with compositions of red rice fermentation products |
WO1998014177A1 (en) * | 1996-09-30 | 1998-04-09 | Pharmanex Incorporated | Methods and compositions employing red yeast fermentation products |
US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
US6436406B1 (en) * | 2000-06-15 | 2002-08-20 | A. Glenn Braswell | Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
CN1982327B (en) | 2005-12-13 | 2010-05-05 | 北京师范大学 | Phytosterin compound and its use |
CN101104003A (en) | 2006-07-11 | 2008-01-16 | 北京北大维信生物科技有限公司 | Xuezhikang purpose-made monascus anti-cancer new use |
CN101313919B (en) * | 2007-05-31 | 2012-08-08 | 北京北大维信生物科技有限公司 | Rice fermented with red yeast extract, preparation method and quality detection method thereof |
US20090004290A1 (en) | 2007-06-30 | 2009-01-01 | Voelker Kirk G | Red yeast rice compound for cancer chemoprevention |
CN101469014B (en) | 2007-12-27 | 2011-06-15 | 北京北大维信生物科技有限公司 | Novel compound and separation method thereof |
US7993666B2 (en) | 2008-04-18 | 2011-08-09 | Warsaw Orthopedic, Inc. | Methods and compositions for treating pain comprising a statin |
WO2011003284A1 (en) | 2009-07-09 | 2011-01-13 | 北京北大维信生物科技有限公司 | Compound and preparation method and use thereof |
CN101942003A (en) * | 2009-07-09 | 2011-01-12 | 北京北大维信生物科技有限公司 | Compound and preparation method thereof |
CN102617533B (en) * | 2011-02-01 | 2014-08-27 | 北京北大维信生物科技有限公司 | Compound separated from red yeast rice, its preparation method and application |
CN103211822B (en) * | 2012-01-18 | 2017-09-22 | 北京北大维信生物科技有限公司 | A kind of purposes of the suppression lipase of sterol derivative |
TWI518094B (en) * | 2011-12-26 | 2016-01-21 | Univ Beijing Peking Wbl Biotech Co Ltd | One kind of derivatives of sterols, their preparation and use |
CN103169713B (en) * | 2011-12-26 | 2015-07-29 | 北京北大维信生物科技有限公司 | A kind of sterol derivative is preparing the purposes in cancer therapy drug |
CN103172693B (en) * | 2011-12-26 | 2016-01-27 | 北京北大维信生物科技有限公司 | A kind of sterol derivative, Preparation Method And The Use |
WO2013113294A1 (en) * | 2012-02-02 | 2013-08-08 | 北京北大维信生物科技有限公司 | Sterol derivative, preparation method therefor and use thereof |
CN105985244A (en) * | 2015-02-04 | 2016-10-05 | 北京北大维信生物科技有限公司 | Compound as well as separation method, synthetic method and application thereof |
-
2012
- 2012-12-25 TW TW101149915A patent/TWI518094B/en active
- 2012-12-25 US US14/368,494 patent/US10889612B2/en active Active
- 2012-12-25 CN CN201280062316.2A patent/CN104024270B/en active Active
- 2012-12-25 ES ES12862540.7T patent/ES2666459T3/en active Active
- 2012-12-25 WO PCT/CN2012/087360 patent/WO2013097681A1/en active Application Filing
- 2012-12-25 MY MYPI2014001905A patent/MY172011A/en unknown
- 2012-12-25 EP EP12862540.7A patent/EP2799444B1/en active Active
- 2012-12-25 SG SG11201403618PA patent/SG11201403618PA/en unknown
-
2014
- 2014-11-28 HK HK14112046.3A patent/HK1198539A1/en unknown
-
2020
- 2020-10-15 US US17/071,963 patent/US11634454B2/en active Active
- 2020-10-15 US US17/071,958 patent/US20210024570A1/en active Pending
-
2022
- 2022-08-08 US US17/818,302 patent/US11845774B2/en active Active
- 2022-08-09 US US17/818,667 patent/US11845775B2/en active Active
- 2022-08-17 US US17/820,553 patent/US20220402967A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046022A (en) * | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
Also Published As
Publication number | Publication date |
---|---|
US10889612B2 (en) | 2021-01-12 |
SG11201403618PA (en) | 2014-09-26 |
CN104024270B (en) | 2016-07-06 |
HK1198539A1 (en) | 2015-05-15 |
US20150031657A1 (en) | 2015-01-29 |
WO2013097681A1 (en) | 2013-07-04 |
US11634454B2 (en) | 2023-04-25 |
US11845775B2 (en) | 2023-12-19 |
EP2799444A4 (en) | 2015-07-01 |
TW201345920A (en) | 2013-11-16 |
EP2799444B1 (en) | 2018-01-24 |
US20210047364A1 (en) | 2021-02-18 |
EP2799444A1 (en) | 2014-11-05 |
US20220389051A1 (en) | 2022-12-08 |
US20220387453A1 (en) | 2022-12-08 |
MY172011A (en) | 2019-11-11 |
US20210024570A1 (en) | 2021-01-28 |
US11845774B2 (en) | 2023-12-19 |
TWI518094B (en) | 2016-01-21 |
ES2666459T3 (en) | 2018-05-04 |
CN104024270A (en) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11845775B2 (en) | Sterol derivatives and preparation method and uses thereof | |
JP6302102B2 (en) | A compound isolated from MONASCUS PURPUREUS, its preparation and use | |
Gui-Yang et al. | Three new polyoxygenated bergamotanes from the endophytic fungus Penicillium purpurogenum IMM 003 and their inhibitory activity against pancreatic lipase | |
US10093695B2 (en) | Sterol derivative, preparation method therefor and use thereof | |
Wei et al. | Triterpenoids as bivalent and dual inhibitors of acetylcholinesterase/butyrylcholinesterase from the fruiting bodies of Inonotus obliquus | |
US10099998B2 (en) | Compound, and separation method, synthesis method and use thereof | |
CN103172693B (en) | A kind of sterol derivative, Preparation Method And The Use | |
CN103211822B (en) | A kind of purposes of the suppression lipase of sterol derivative | |
CN103169713B (en) | A kind of sterol derivative is preparing the purposes in cancer therapy drug | |
CN115745790A (en) | Eight-ring five-terpenoid compound in lancang yellow fir and preparation and application thereof | |
CN115873057A (en) | 26-carboxylic acid triterpene compound in sequoia, preparation method thereof and application thereof as acetyl coenzyme A carboxylase inhibitor | |
CN115925775A (en) | Triterpenoid compound and preparation method and application thereof | |
Muhammad et al. | Chemodiverse monoterpene indole alkaloids from Kopsia teoi, inhibitory potential against α-amylase, and their molecular docking studies | |
KR0154504B1 (en) | Cholesteryl ester transfer protein inhibitor and the manufacturing method therefor | |
CN115925538A (en) | Terpenoid heterodimer in lancang yellow fir and application of terpenoid heterodimer in preparation of acetyl coenzyme A carboxylase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUAN, ZHENWEN;GUO, SHUREN;LI, XUEMEI;REEL/FRAME:065189/0324 Effective date: 20140710 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |